mirror of
https://github.com/msberends/AMR.git
synced 2026-08-19 22:39:28 +02:00
4.6 MiB
4.6 MiB
| 1 | guideline | version | type | host | method | site | mo | rank_index | ab | ref_tbl | disk_dose | breakpoint_S | breakpoint_R | uti | is_SDD | is_screening | note | sheet |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ampicillin | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 3 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ampicillin | Enterobacterales | 10 mcg | 14 | 14 | FALSE | FALSE | FALSE | [1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 4 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ampicillin-sulbactam | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 5 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ampicillin-sulbactam | Enterobacterales | 10/10 mcg | 14 | 14 | FALSE | FALSE | FALSE | [1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 6 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [C] Susceptibility inferred from ampicillin. | Enterobacterales |
| 7 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin | Enterobacterales | / mcg | Note | Note | FALSE | FALSE | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [C] Susceptibility inferred from ampicillin. | Enterobacterales |
| 8 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 9 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid | Enterobacterales | 20/10 mcg | 19 | 19 | FALSE | FALSE | FALSE | [1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 10 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid (uncomplicated UTI only) | Enterobacterales | NA | 32 | 32 | FALSE | FALSE | FALSE | [1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 11 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid (uncomplicated UTI only) | Enterobacterales | 20/10 mcg | 16 | 16 | FALSE | FALSE | FALSE | [1/A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 12 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Piperacillin | Enterobacterales | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 13 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Piperacillin | Enterobacterales | 30 mcg | 20 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 14 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Piperacillin-tazobactam | Enterobacterales | NA | 8 | 16 | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 15 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Piperacillin-tazobactam | Enterobacterales | 30/6 mcg | 20 | 17 | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 16 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ticarcillin | Enterobacterales | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 17 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ticarcillin | Enterobacterales | 75 mcg | 23 | 20 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 18 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ticarcillin-clavulanic acid | Enterobacterales | NA | 8 | 16 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 19 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ticarcillin-clavulanic acid | Enterobacterales | 75/10 mcg | 23 | 20 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 20 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Temocillin | Enterobacterales | NA | Note | Note | FALSE | FALSE | FALSE | [5] Breakpoints still under consideration. | Enterobacterales |
| 21 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Temocillin | Enterobacterales | NA | Note | Note | FALSE | FALSE | FALSE | [5] Breakpoints still under consideration. | Enterobacterales |
| 22 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Mecillinam (uncomplicated UTI only) E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone for E. coli. | Enterobacterales |
| 23 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Mecillinam (uncomplicated UTI only) E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | 10 mcg | 15 | 15 | FALSE | FALSE | FALSE | [6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone for E. coli. | Enterobacterales |
| 24 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefadroxil (uncomplicated UTI only) | Enterobacterales | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 25 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefadroxil (uncomplicated UTI only) | Enterobacterales | 30 mcg | 12 | 12 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 26 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefalexin (uncomplicated UTI only) | Enterobacterales | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 27 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefalexin (uncomplicated UTI only) | Enterobacterales | 30 mcg | 14 | 14 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 28 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefepime | Enterobacterales | NA | 1 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 29 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefepime | Enterobacterales | 30 mcg | 27 | 24 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 30 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefixime (uncomplicated UTI only) | Enterobacterales | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 31 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefixime (uncomplicated UTI only) | Enterobacterales | 5 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 32 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefotaxime | Enterobacterales | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 33 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefotaxime | Enterobacterales | 5 mcg | 20 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 34 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefoxitin (screen) | Enterobacterales | 30 mcg | 19 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 35 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefpodoxime (uncomplicated UTI only) | Enterobacterales | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 36 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefpodoxime (uncomplicated UTI only) | Enterobacterales | 10 mcg | 21 | 21 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 37 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftaroline | Enterobacterales | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 38 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftaroline | Enterobacterales | 5 mcg | 23 | 23 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 39 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftazidime | Enterobacterales | NA | 1 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 40 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftazidime | Enterobacterales | 10 mcg | 22 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 41 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftazidime-avibactam | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Enterobacterales |
| 42 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftazidime-avibactam | Enterobacterales | 10/4 mcg | 13 | 13 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Enterobacterales |
| 43 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftibuten (UTI only) | Enterobacterales | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 44 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftibuten (UTI only) | Enterobacterales | 30 mcg | 23 | 23 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 45 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftobiprole | Enterobacterales | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 46 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftobiprole | Enterobacterales | 5 mcg | 23 | 23 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 47 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftolozane-tazobactam | Enterobacterales | NA | 1 | 1 | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 48 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftolozane-tazobactam | Enterobacterales | 30/10 mcg | 23 | 23 | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 49 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftriaxone | Enterobacterales | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 50 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftriaxone | Enterobacterales | 30 mcg | 25 | 22 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 51 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 52 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | 30 mcg | 19 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 53 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 54 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | 30 mcg | 19 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 55 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ertapenem | Enterobacterales | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 56 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ertapenem | Enterobacterales | 10 mcg | 25 | 25 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 57 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Imipenem | Enterobacterales | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 58 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Imipenem | Enterobacterales | 10 mcg | 22 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 59 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Imipenem, Morganella morganii,Proteus spp. and Providencia spp. | Enterobacterales | NA | 0.125 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 60 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Imipenem, Morganella morganii,Proteus spp. and Providencia spp. | Enterobacterales | 10 mcg | 50 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 61 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Meropenem | Enterobacterales | NA | 2 | 8 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 62 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Meropenem | Enterobacterales | 10 mcg | 22 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 63 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Meropenem-vaborbactam | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Enterobacterales |
| 64 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Meropenem-vaborbactam | Enterobacterales | IP mcg | IP | IP | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Enterobacterales |
| 65 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Aztreonam | Enterobacterales | NA | 1 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 66 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Aztreonam | Enterobacterales | 30 mcg | 26 | 21 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 67 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ciprofloxacin | Enterobacterales | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 68 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ciprofloxacin | Enterobacterales | 5 mcg | 25 | 22 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 69 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ciprofloxacin, Salmonella spp. | Enterobacterales | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | [A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | Enterobacterales |
| 70 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ciprofloxacin, Salmonella spp. | Enterobacterales | NA | Note | Note | FALSE | FALSE | FALSE | [A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | Enterobacterales |
| 71 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Pefloxacin (screen),Salmonella spp. | Enterobacterales | 5 mcg | 24 | 24 | FALSE | FALSE | FALSE | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | Enterobacterales |
| 72 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Levofloxacin | Enterobacterales | NA | 0.5 | 1 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 73 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Levofloxacin | Enterobacterales | 5 mcg | 23 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 74 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Moxifloxacin | Enterobacterales | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 75 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Moxifloxacin | Enterobacterales | 5 mcg | 22 | 22 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 76 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Norfloxacin (uncomplicated UTI only) | Enterobacterales | NA | 0.5 | 1 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 77 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Norfloxacin (uncomplicated UTI only) | Enterobacterales | 10 mcg | 22 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 78 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Ofloxacin | Enterobacterales | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 79 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Ofloxacin | Enterobacterales | 5 mcg | 24 | 22 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 80 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Amikacin | Enterobacterales | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 81 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Amikacin | Enterobacterales | 30 mcg | 18 | 15 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 82 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Gentamicin | Enterobacterales | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 83 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Gentamicin | Enterobacterales | 10 mcg | 17 | 14 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 84 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Netilmicin | Enterobacterales | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 85 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Netilmicin | Enterobacterales | 10 mcg | 15 | 12 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 86 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Tobramycin | Enterobacterales | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 87 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Tobramycin | Enterobacterales | 10 mcg | 17 | 14 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 88 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Eravacycline, E. coli | Enterobacterales | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 89 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Eravacycline, E. coli | Enterobacterales | IP mcg | IP | IP | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 90 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Tigecycline,E. coli and C. koseri | Enterobacterales | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] Tigecycline has poor activity against Morganella morganii, Proteus spp. and Providencia spp. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method. | Enterobacterales |
| 91 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Tigecycline,E. coli and C. koseri | Enterobacterales | 15 mcg | 18 | 18 | FALSE | FALSE | FALSE | [3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] Tigecycline has poor activity against Morganella morganii, Proteus spp. and Providencia spp. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method. | Enterobacterales |
| 92 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Chloramphenicol | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 93 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Chloramphenicol | Enterobacterales | 30 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 94 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Colistin | Enterobacterales | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Enterobacterales |
| 95 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Colistin | Enterobacterales | NA | Note | Note | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Enterobacterales |
| 96 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Fosfomycin iv | Enterobacterales | NA | 32 | 32 | FALSE | FALSE | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 97 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Fosfomycin iv | Enterobacterales | 200 mcg | 24 | 24 | FALSE | FALSE | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 98 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Fosfomycin oral (uncomplicated UTI only) | Enterobacterales | NA | 32 | 32 | FALSE | FALSE | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 99 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Fosfomycin oral (uncomplicated UTI only) | Enterobacterales | 200 mcg | 24 | 24 | FALSE | FALSE | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 100 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Nitrofurantoin (uncomplicated UTI only), E. coli | Enterobacterales | NA | 64 | 64 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 101 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Nitrofurantoin (uncomplicated UTI only), E. coli | Enterobacterales | 100 mcg | 11 | 11 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 102 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Nitroxoline (uncomplicated UTI only), E. coli | Enterobacterales | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 103 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Nitroxoline (uncomplicated UTI only), E. coli | Enterobacterales | 30 mcg | 15 | 15 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 104 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Trimethoprim (uncomplicated UTI only) | Enterobacterales | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 105 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Trimethoprim (uncomplicated UTI only) | Enterobacterales | 5 mcg | 18 | 15 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 106 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterobacterales | NA | Trimethoprim-sulfamethoxazole | Enterobacterales | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 107 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterobacterales | NA | Trimethoprim-sulfamethoxazole | Enterobacterales | 1.25/23.75 mcg | 14 | 11 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 108 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Piperacillin | Pseudomonas spp. | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 109 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Piperacillin | Pseudomonas spp. | 30 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 110 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Piperacillin-tazobactam | Pseudomonas spp. | NA | 16 | 16 | FALSE | FALSE | FALSE | [1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 111 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Piperacillin-tazobactam | Pseudomonas spp. | 30/6 mcg | 18 | 18 | FALSE | FALSE | FALSE | [1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 112 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ticarcillin | Pseudomonas spp. | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 113 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ticarcillin | Pseudomonas spp. | 75 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 114 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ticarcillin-clavulanic acid | Pseudomonas spp. | NA | 16 | 16 | FALSE | FALSE | FALSE | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Pseudomonas |
| 115 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ticarcillin-clavulanic acid | Pseudomonas spp. | 75/10 mcg | 18 | 18 | FALSE | FALSE | FALSE | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Pseudomonas |
| 116 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Cefepime | Pseudomonas spp. | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 117 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Cefepime | Pseudomonas spp. | 30 mcg | 21 | 21 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 118 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftazidime | Pseudomonas spp. | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 119 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftazidime | Pseudomonas spp. | 10 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 120 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftazidime-avibactam, P. aeruginosa | Pseudomonas spp. | NA | 8 | 8 | FALSE | FALSE | FALSE | [1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Pseudomonas |
| 121 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftazidime-avibactam, P. aeruginosa | Pseudomonas spp. | 10/4 mcg | 17 | 17 | FALSE | FALSE | FALSE | [1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Pseudomonas |
| 122 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftobiprole | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 123 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftobiprole | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 124 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftolozane-tazobactam, P. aeruginosa | Pseudomonas spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | [2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 125 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftolozane-tazobactam, P. aeruginosa | Pseudomonas spp. | 30/10 mcg | 24 | 24 | FALSE | FALSE | FALSE | [2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 126 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Imipenem | Pseudomonas spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 127 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Imipenem | Pseudomonas spp. | 10 mcg | 20 | 20 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 128 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Meropenem | Pseudomonas spp. | NA | 2 | 8 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 129 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Meropenem | Pseudomonas spp. | 10 mcg | 24 | 18 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 130 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Meropenem-vaborbactam, P. aeruginosa | Pseudomonas spp. | NA | 8 | 8 | FALSE | FALSE | FALSE | [1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Pseudomonas |
| 131 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Meropenem-vaborbactam, P. aeruginosa | Pseudomonas spp. | IP mcg | IP | IP | FALSE | FALSE | FALSE | [1] Breakpoints are based on high dose therapy, see table of dosages. | [1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Pseudomonas |
| 132 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Aztreonam | Pseudomonas spp. | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 133 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Aztreonam | Pseudomonas spp. | 30 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 134 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ciprofloxacin | Pseudomonas spp. | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 135 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ciprofloxacin | Pseudomonas spp. | 5 mcg | 26 | 26 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 136 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Levofloxacin | Pseudomonas spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 137 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Levofloxacin | Pseudomonas spp. | 5 mcg | 22 | 22 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 138 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Amikacin | Pseudomonas spp. | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 139 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Amikacin | Pseudomonas spp. | 30 mcg | 18 | 15 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 140 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Gentamicin | Pseudomonas spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 141 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Gentamicin | Pseudomonas spp. | 10 mcg | 15 | 15 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 142 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Netilmicin | Pseudomonas spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 143 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Netilmicin | Pseudomonas spp. | 10 mcg | 12 | 12 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 144 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Tobramycin | Pseudomonas spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 145 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Tobramycin | Pseudomonas spp. | 10 mcg | 16 | 16 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 146 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Colistin | Pseudomonas spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Pseudomonas |
| 147 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Colistin | Pseudomonas spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Pseudomonas |
| 148 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Stenotrophomonas maltophilia | NA | Trimethoprim-sulfamethoxazole | Stenotrophomonas maltophilia | NA | 4 | 4 | FALSE | FALSE | FALSE | [A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | S.maltophilia |
| 149 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Stenotrophomonas maltophilia | NA | Trimethoprim-sulfamethoxazole | Stenotrophomonas maltophilia | 1.25/23.75 mcg | 16 | 16 | FALSE | FALSE | FALSE | [A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | S.maltophilia |
| 150 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ampicillin-sulbactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 151 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ampicillin-sulbactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 152 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Piperacillin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 153 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Piperacillin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 154 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Piperacillin-tazobactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 155 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Piperacillin-tazobactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 156 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ticarcillin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 157 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ticarcillin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 158 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ticarcillin-clavulanic acid | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 159 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ticarcillin-clavulanic acid | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 160 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Imipenem | Acinetobacter spp. | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 161 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Imipenem | Acinetobacter spp. | 10 mcg | 24 | 21 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 162 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Meropenem | Acinetobacter spp. | NA | 2 | 8 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 163 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Meropenem | Acinetobacter spp. | 10 mcg | 21 | 15 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 164 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Meropenem-vaborbactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 165 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Meropenem-vaborbactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 166 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ciprofloxacin | Acinetobacter spp. | NA | 0.06 | 1 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 167 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ciprofloxacin | Acinetobacter spp. | 5 mcg | 50 | 21 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 168 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Levofloxacin | Acinetobacter spp. | NA | 0.5 | 1 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 169 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Levofloxacin | Acinetobacter spp. | 5 mcg | 23 | 20 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 170 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Amikacin | Acinetobacter spp. | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 171 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Amikacin | Acinetobacter spp. | 30 mcg | 19 | 17 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 172 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Gentamicin | Acinetobacter spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 173 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Gentamicin | Acinetobacter spp. | 10 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 174 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Netilmicin | Acinetobacter spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 175 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Netilmicin | Acinetobacter spp. | 10 mcg | 16 | 16 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 176 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Tobramycin | Acinetobacter spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 177 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Tobramycin | Acinetobacter spp. | 10 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 178 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Eravacycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 179 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Eravacycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 180 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Minocycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 181 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Minocycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 182 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Tigecycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 183 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Tigecycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 184 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Colistin | Acinetobacter spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Acinetobacter |
| 185 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Colistin | Acinetobacter spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Acinetobacter |
| 186 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Trimethoprim-sulfamethoxazole | Acinetobacter spp. | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 187 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Trimethoprim-sulfamethoxazole | Acinetobacter spp. | 1.25/23.75 mcg | 14 | 11 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 188 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Benzylpenicillin,S. aureus | Staphylococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase. | Staphylococcus |
| 189 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Benzylpenicillin,S. aureus | Staphylococcus spp. | 1 unit | 26 | 26 | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase. | Staphylococcus |
| 190 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Benzylpenicillin,S. lugdunensis | Staphylococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 191 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Benzylpenicillin,S. lugdunensis | Staphylococcus spp. | 1 unit | 26 | 26 | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 192 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Benzylpenicillin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | Staphylococcus |
| 193 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ampicillin,S. saprophyticus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 194 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ampicillin,S. saprophyticus | Staphylococcus spp. | 2 mcg | 18 | 18 | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 195 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ampicillin-sulbactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 196 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ampicillin-sulbactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 197 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Amoxicillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 198 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Amoxicillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 199 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Amoxicillin-clavulanic acid | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 200 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Amoxicillin-clavulanic acid | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 201 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Piperacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 202 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Piperacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 203 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Piperacillin-tazobactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 204 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Piperacillin-tazobactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 205 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ticarcillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 206 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ticarcillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 207 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ticarcillin-clavulanic acid | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 208 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ticarcillin-clavulanic acid | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 209 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Phenoxymethylpenicillin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 210 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Phenoxymethylpenicillin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 211 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Phenoxymethylpenicillin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | Staphylococcus |
| 212 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Oxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [E] For screening for methicillin resistance in S. pseudintermedius, see Note C on cephalosporins. | Staphylococcus |
| 213 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Oxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [E] For screening for methicillin resistance in S. pseudintermedius, see Note C on cephalosporins. | Staphylococcus |
| 214 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 215 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 216 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Dicloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 217 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Dicloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 218 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Flucloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 219 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Flucloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 220 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefaclor | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 221 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefaclor | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 222 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefadroxil | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 223 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefadroxil | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 224 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefalexin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 225 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefalexin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 226 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefazolin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 227 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefazolin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 228 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefepime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 229 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefepime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 230 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefotaxime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 231 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefotaxime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 232 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefoxitin (screen), S. aureus and coagulase-negative staphylococci other than S. epidermidis | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2] For dosing, see table of dosages. 2.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm. | Staphylococcus |
| 233 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefoxitin (screen), S. aureus and coagulase-negative staphylococci other than S. epidermidis | Staphylococcus spp. | 30 mcg | 22 | 22 | FALSE | FALSE | FALSE | [2] For dosing, see table of dosages. 2.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm. | Staphylococcus |
| 234 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefoxitin (screen), S. epidermidis | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm. | Staphylococcus |
| 235 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefoxitin (screen), S. epidermidis | Staphylococcus spp. | 30 mcg | 25 | 25 | FALSE | FALSE | FALSE | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm. | Staphylococcus |
| 236 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefoxitin (screen), S. pseudintermedius | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [C] Cefoxitin screen for methicillin resistance in S. pseudintermedius is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm to screen for methicillin resistance. | Staphylococcus |
| 237 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefpodoxime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 238 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefpodoxime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 239 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ceftaroline, S. aureus (indications other than pneumonia) | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 240 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ceftaroline, S. aureus (indications other than pneumonia) | Staphylococcus spp. | 5 mcg | 20 | 17 | FALSE | FALSE | FALSE | [4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 241 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ceftaroline, S. aureus (pneumonia) | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | [4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 242 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ceftaroline, S. aureus (pneumonia) | Staphylococcus spp. | 5 mcg | 20 | 20 | FALSE | FALSE | FALSE | [4/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 243 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ceftobiprole, S. aureus | Staphylococcus spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [6/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing. | Staphylococcus |
| 244 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ceftobiprole, S. aureus | Staphylococcus spp. | 5 mcg | 17 | 17 | FALSE | FALSE | FALSE | [6/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing. | Staphylococcus |
| 245 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ceftriaxone | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 246 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ceftriaxone | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 247 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefuroxime iv | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 248 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefuroxime iv | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 249 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefuroxime oral | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 250 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefuroxime oral | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 251 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ertapenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 252 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ertapenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 253 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Imipenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 254 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Imipenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 255 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Meropenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 256 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Meropenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 257 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Meropenem-vaborbactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 258 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Meropenem-vaborbactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 259 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ciprofloxacin, S. aureus | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 260 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ciprofloxacin, S. aureus | Staphylococcus spp. | 5 mcg | 21 | 21 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 261 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ciprofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 262 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ciprofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | 5 mcg | 24 | 24 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 263 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Levofloxacin, S. aureus | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 264 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Levofloxacin, S. aureus | Staphylococcus spp. | 5 mcg | 22 | 22 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 265 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Levofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 266 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Levofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | 5 mcg | 24 | 24 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 267 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Moxifloxacin, S. aureus | Staphylococcus spp. | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 268 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Moxifloxacin, S. aureus | Staphylococcus spp. | 5 mcg | 25 | 25 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 269 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Moxifloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 270 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Moxifloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | 5 mcg | 28 | 28 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 271 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Norfloxacin (screen) | Staphylococcus spp. | 10 mcg | 17 | Note | FALSE | FALSE | FALSE | [B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Staphylococcus |
| 272 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ofloxacin, S. aureus | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 273 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ofloxacin, S. aureus | Staphylococcus spp. | 5 mcg | 20 | 20 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 274 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 275 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | 5 mcg | 24 | 24 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 276 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Amikacin, S. aureus | Staphylococcus spp. | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 277 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Amikacin, S. aureus | Staphylococcus spp. | 30 mcg | 18 | 16 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 278 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Amikacin,Coagulase-negative staphylococci | Staphylococcus spp. | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 279 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Amikacin,Coagulase-negative staphylococci | Staphylococcus spp. | 30 mcg | 22 | 19 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 280 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Gentamicin, S. aureus | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 281 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Gentamicin, S. aureus | Staphylococcus spp. | 10 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 282 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Gentamicin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 283 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Gentamicin, Coagulase-negative staphylococci | Staphylococcus spp. | 10 mcg | 22 | 22 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 284 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Netilmicin, S. aureus | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 285 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Netilmicin, S. aureus | Staphylococcus spp. | 10 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 286 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Netilmicin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 287 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Netilmicin, Coagulase-negative staphylococci | Staphylococcus spp. | 10 mcg | 22 | 22 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 288 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Tobramycin, S. aureus | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 289 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Tobramycin, S. aureus | Staphylococcus spp. | 10 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 290 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Tobramycin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 291 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Tobramycin, Coagulase-negative staphylococci | Staphylococcus spp. | 10 mcg | 22 | 22 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 292 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Dalbavancin | Staphylococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 293 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Dalbavancin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 294 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Oritavancin, S. aureus | Staphylococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 295 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Oritavancin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 296 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Teicoplanin, S. aureus | Staphylococcus spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 297 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Teicoplanin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 298 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Teicoplanin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 299 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Teicoplanin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 300 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Telavancin,MRSA | Staphylococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 301 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Telavancin,MRSA | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 302 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Vancomycin, S. aureus | Staphylococcus spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 303 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Vancomycin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 304 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Vancomycin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 305 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Vancomycin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 306 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Azithromycin | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 307 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Azithromycin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 308 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Clarithromycin | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 309 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Clarithromycin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 310 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Erythromycin | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 311 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Erythromycin | Staphylococcus spp. | 15 mcg | 21 | 18 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 312 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Roxithromycin | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 313 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Roxithromycin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 314 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Telithromycin | Staphylococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 315 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Telithromycin | Staphylococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 316 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Clindamycin | Staphylococcus spp. | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | Staphylococcus |
| 317 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Clindamycin | Staphylococcus spp. | 2 mcg | 22 | 19 | FALSE | FALSE | FALSE | [B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | Staphylococcus |
| 318 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Quinupristin-dalfopristin | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 319 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Quinupristin-dalfopristin | Staphylococcus spp. | 15 mcg | 21 | 18 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 320 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Doxycycline | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 321 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Doxycycline | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 322 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Eravacycline, S. aureus | Staphylococcus spp. | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 323 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Eravacycline, S. aureus | Staphylococcus spp. | IP mcg | IP | IP | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 324 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Minocycline | Staphylococcus spp. | NA | 0.5 | 1 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 325 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Minocycline | Staphylococcus spp. | 30 mcg | 23 | 20 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 326 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Tetracycline | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 327 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Tetracycline | Staphylococcus spp. | 30 mcg | 22 | 19 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 328 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Tigecycline | Staphylococcus spp. | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | Staphylococcus |
| 329 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Tigecycline | Staphylococcus spp. | 15 mcg | 18 | 18 | FALSE | FALSE | FALSE | [3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | Staphylococcus |
| 330 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Linezolid | Staphylococcus spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | [A] Examine zone edges with transmitted light (plate held up to light). | Staphylococcus |
| 331 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Linezolid | Staphylococcus spp. | 10 mcg | 21 | 21 | FALSE | FALSE | FALSE | [A] Examine zone edges with transmitted light (plate held up to light). | Staphylococcus |
| 332 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Tedizolid | Staphylococcus spp. | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [1] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [B] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | Staphylococcus |
| 333 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Tedizolid | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [B] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | Staphylococcus |
| 334 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Chloramphenicol | Staphylococcus spp. | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 335 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Chloramphenicol | Staphylococcus spp. | 30 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 336 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Daptomycin | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | [2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method. | Staphylococcus |
| 337 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Daptomycin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method. | Staphylococcus |
| 338 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Fosfomycin iv | Staphylococcus spp. | NA | 32 | 32 | FALSE | FALSE | FALSE | [3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method. | Staphylococcus |
| 339 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Fosfomycin iv | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [A] Use an MIC method. | Staphylococcus |
| 340 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Fusidic acid | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 341 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Fusidic acid | Staphylococcus spp. | 10 mcg | 24 | 24 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 342 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Nitrofurantoin (uncomplicated UTI only), S. saprophyticus | Staphylococcus spp. | NA | 64 | 64 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 343 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Nitrofurantoin (uncomplicated UTI only), S. saprophyticus | Staphylococcus spp. | 100 mcg | 13 | 13 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 344 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Nitroxoline (uncomplicated UTI only), S. saprophyticus | Staphylococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 345 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Nitroxoline (uncomplicated UTI only), S. saprophyticus | Staphylococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 346 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Rifampicin | Staphylococcus spp. | NA | 0.06 | 0.5 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 347 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Rifampicin | Staphylococcus spp. | 5 mcg | 26 | 23 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 348 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | Staphylococcus spp. | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 349 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | Staphylococcus spp. | 5 mcg | 17 | 14 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 350 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Trimethoprim-sulfamethoxazole | Staphylococcus spp. | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 351 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Trimethoprim-sulfamethoxazole | Staphylococcus spp. | 1.25/23.75 mcg | 17 | 14 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 352 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Ampicillin | Enterococcus spp. | NA | 4 | 8 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 353 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Ampicillin | Enterococcus spp. | 2 mcg | 10 | 8 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 354 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Ampicillin-sulbactam | Enterococcus spp. | NA | 4 | 8 | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 355 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Ampicillin-sulbactam | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 356 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Amoxicillin | Enterococcus spp. | NA | 4 | 8 | FALSE | FALSE | FALSE | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 357 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Amoxicillin | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 358 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Amoxicillin-clavulanic acid | Enterococcus spp. | NA | 4 | 8 | FALSE | FALSE | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 359 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Amoxicillin-clavulanic acid | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 360 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Piperacillin | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 361 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Piperacillin | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 362 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Piperacillin-tazobactam | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 363 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Piperacillin-tazobactam | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 364 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Imipenem | Enterococcus spp. | NA | 4 | 8 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 365 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Imipenem | Enterococcus spp. | 10 mcg | 21 | 18 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 366 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Ciprofloxacin (uncomplicated UTI only) | Enterococcus spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Enterococcus |
| 367 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Ciprofloxacin (uncomplicated UTI only) | Enterococcus spp. | 5 mcg | 15 | 15 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Enterococcus |
| 368 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Levofloxacin (uncomplicated UTI only) | Enterococcus spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Enterococcus |
| 369 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Levofloxacin (uncomplicated UTI only) | Enterococcus spp. | 5 mcg | 15 | 15 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Enterococcus |
| 370 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Norfloxacin (screen) | Enterococcus spp. | 10 mcg | 12 | 12 | FALSE | FALSE | FALSE | [B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. | Enterococcus |
| 371 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Amikacin | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 372 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Amikacin | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 373 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Gentamicin (test for high-level aminoglycoside resistance) | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 374 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Gentamicin (test for high-level aminoglycoside resistance) | Enterococcus spp. | 30 mcg | Note | Note | FALSE | FALSE | FALSE | [2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 375 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Netilmicin | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 376 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Netilmicin | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 377 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Streptomycin (test for high-level streptomycin resistance) | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 378 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Streptomycin (test for high-level streptomycin resistance) | Enterococcus spp. | 300 mcg | Note | Note | FALSE | FALSE | FALSE | [3/B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 379 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Tobramycin | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 380 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Tobramycin | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2/A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 381 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Dalbavancin | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 382 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Dalbavancin | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 383 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Oritavancin | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 384 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Oritavancin | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 385 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Teicoplanin | Enterococcus spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 386 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Teicoplanin | Enterococcus spp. | 30 mcg | 16 | 16 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 387 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Telavancin | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 388 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Telavancin | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 389 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Vancomycin | Enterococcus spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | [A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation. | Enterococcus |
| 390 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Vancomycin | Enterococcus spp. | 5 mcg | 12 | 12 | FALSE | FALSE | FALSE | [A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation. | Enterococcus |
| 391 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Quinupristin-dalfopristin, E. faecium | Enterococcus spp. | NA | 1 | 4 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 392 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Quinupristin-dalfopristin, E. faecium | Enterococcus spp. | 15 mcg | 22 | 20 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 393 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Eravacycline | Enterococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 394 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Eravacycline | Enterococcus spp. | IP mcg | IP | IP | FALSE | FALSE | FALSE | NA | Enterococcus |
| 395 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Tigecycline | Enterococcus spp. | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | Enterococcus |
| 396 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Tigecycline | Enterococcus spp. | 15 mcg | 18 | 18 | FALSE | FALSE | FALSE | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | Enterococcus |
| 397 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Linezolid | Enterococcus spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 398 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Linezolid | Enterococcus spp. | 10 mcg | 19 | 19 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 399 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Tedizolid | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 400 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Tedizolid | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 401 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Daptomycin | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 402 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Daptomycin | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 403 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Nitrofurantoin (uncomplicated UTI only), E. faecalis | Enterococcus spp. | NA | 64 | 64 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 404 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Nitrofurantoin (uncomplicated UTI only), E. faecalis | Enterococcus spp. | 100 mcg | 15 | 15 | FALSE | FALSE | FALSE | NA | Enterococcus |
| 405 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Nitroxoline (uncomplicated UTI only) | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 406 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Nitroxoline (uncomplicated UTI only) | Enterococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterococcus |
| 407 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | Enterococcus |
| 408 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | Enterococcus spp. | 5 mcg | Note | Note | FALSE | FALSE | FALSE | [2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | Enterococcus |
| 409 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Enterococcus spp. | NA | Trimethoprim-sulfamethoxazole | Enterococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | Enterococcus |
| 410 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Enterococcus spp. | NA | Trimethoprim-sulfamethoxazole | Enterococcus spp. | 1.25/23.75 mcg | Note | Note | FALSE | FALSE | FALSE | [2/A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | Enterococcus |
| 411 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Benzylpenicillin | Streptococcus groups A, B, C and G | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 412 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Benzylpenicillin | Streptococcus groups A, B, C and G | 1 unit | 18 | 18 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 413 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ampicillin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 414 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ampicillin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 415 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ampicillin-sulbactam | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 416 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ampicillin-sulbactam | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 417 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 418 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 419 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin-clavulanic acid | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 420 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Amoxicillin-clavulanic acid | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 421 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Piperacillin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 422 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Piperacillin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 423 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Piperacillin-tazobactam | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 424 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Piperacillin-tazobactam | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 425 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Phenoxymethylpenicillin Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 426 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Phenoxymethylpenicillin Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 427 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cloxacillin Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 428 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cloxacillin Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 429 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Dicloxacillin Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 430 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Dicloxacillin Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 431 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Flucloxacillin Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 432 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Flucloxacillin Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 433 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefaclor | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 434 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefaclor | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 435 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefadroxil | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 436 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefadroxil | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 437 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefalexin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 438 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefalexin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 439 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefazolin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 440 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefazolin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 441 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefepime | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 442 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefepime | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 443 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefotaxime | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 444 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefotaxime | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 445 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefpodoxime | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 446 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefpodoxime | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 447 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftaroline | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 448 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftaroline | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 449 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftibuten | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 450 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftibuten | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 451 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftobiprole | Streptococcus groups A, B, C and G | NA | IE | IE | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 452 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftobiprole | Streptococcus groups A, B, C and G | NA | IE | IE | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 453 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftolozane-tazobactam | Streptococcus groups A, B, C and G | NA | IE | IE | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 454 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftolozane-tazobactam | Streptococcus groups A, B, C and G | NA | IE | IE | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 455 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ceftriaxone | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 456 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ceftriaxone | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 457 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime iv | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 458 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime iv | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 459 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime oral | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 460 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Cefuroxime oral | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 461 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Ertapenem | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 462 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Ertapenem | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 463 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Imipenem | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 464 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Imipenem | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 465 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Meropenem | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 466 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Meropenem | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 467 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Meropenem-vaborbactam | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 468 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Meropenem-vaborbactam | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 469 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Levofloxacin | Streptococcus groups A, B, C and G | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Streptococcus A,B,C,G |
| 470 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Levofloxacin | Streptococcus groups A, B, C and G | 5 mcg | 17 | 17 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Streptococcus A,B,C,G |
| 471 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Moxifloxacin | Streptococcus groups A, B, C and G | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Streptococcus A,B,C,G |
| 472 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Moxifloxacin | Streptococcus groups A, B, C and G | 5 mcg | 19 | 19 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Streptococcus A,B,C,G |
| 473 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Norfloxacin (screen) | Streptococcus groups A, B, C and G | 10 mcg | 12 | Note | FALSE | FALSE | FALSE | [B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Streptococcus A,B,C,G |
| 474 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Dalbavancin | Streptococcus groups A, B, C and G | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | Streptococcus A,B,C,G |
| 475 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Dalbavancin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | Streptococcus A,B,C,G |
| 476 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Oritavancin | Streptococcus groups A, B, C and G | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | Streptococcus A,B,C,G |
| 477 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Oritavancin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | Streptococcus A,B,C,G |
| 478 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Teicoplanin | Streptococcus groups A, B, C and G | NA | 2 | 2 | FALSE | FALSE | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | Streptococcus A,B,C,G |
| 479 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Teicoplanin | Streptococcus groups A, B, C and G | 30 mcg | 15 | 15 | FALSE | FALSE | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | Streptococcus A,B,C,G |
| 480 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Telavancin | Streptococcus groups A, B, C and G | NA | IE | IE | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 481 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Telavancin | Streptococcus groups A, B, C and G | NA | IE | IE | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 482 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Vancomycin | Streptococcus groups A, B, C and G | NA | 2 | 2 | FALSE | FALSE | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | Streptococcus A,B,C,G |
| 483 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Vancomycin | Streptococcus groups A, B, C and G | 5 mcg | 13 | 13 | FALSE | FALSE | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | Streptococcus A,B,C,G |
| 484 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Azithromycin | Streptococcus groups A, B, C and G | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 485 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Azithromycin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 486 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Clarithromycin | Streptococcus groups A, B, C and G | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 487 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Clarithromycin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 488 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Erythromycin | Streptococcus groups A, B, C and G | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 489 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Erythromycin | Streptococcus groups A, B, C and G | 15 mcg | 21 | 18 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 490 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Roxithromycin | Streptococcus groups A, B, C and G | NA | 0.5 | 1 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 491 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Roxithromycin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 492 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Telithromycin | Streptococcus groups A, B, C and G | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 493 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Telithromycin | Streptococcus groups A, B, C and G | 15 mcg | 20 | 17 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 494 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Clindamycin | Streptococcus groups A, B, C and G | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | Streptococcus A,B,C,G |
| 495 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Clindamycin | Streptococcus groups A, B, C and G | 2 mcg | 17 | 17 | FALSE | FALSE | FALSE | [B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | Streptococcus A,B,C,G |
| 496 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Doxycycline | Streptococcus groups A, B, C and G | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 497 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Doxycycline | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 498 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Eravacycline | Streptococcus groups A, B, C and G | NA | IE | IE | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 499 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Eravacycline | Streptococcus groups A, B, C and G | NA | IE | IE | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 500 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Minocycline | Streptococcus groups A, B, C and G | NA | 0.5 | 1 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 501 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Minocycline | Streptococcus groups A, B, C and G | 30 mcg | 23 | 20 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 502 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Tetracycline | Streptococcus groups A, B, C and G | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 503 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Tetracycline | Streptococcus groups A, B, C and G | 30 mcg | 23 | 20 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 504 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Tigecycline | Streptococcus groups A, B, C and G | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | Streptococcus A,B,C,G |
| 505 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Tigecycline | Streptococcus groups A, B, C and G | 15 mcg | 19 | 19 | FALSE | FALSE | FALSE | [3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | Streptococcus A,B,C,G |
| 506 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Linezolid | Streptococcus groups A, B, C and G | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 507 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Linezolid | Streptococcus groups A, B, C and G | 10 mcg | 19 | 16 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 508 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Tedizolid | Streptococcus groups A, B, C and G | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | Streptococcus A,B,C,G |
| 509 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Tedizolid | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | Streptococcus A,B,C,G |
| 510 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Chloramphenicol | Streptococcus groups A, B, C and G | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 511 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Chloramphenicol | Streptococcus groups A, B, C and G | 30 mcg | 19 | 19 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 512 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Daptomycin | Streptococcus groups A, B, C and G | NA | 1 | 1 | FALSE | FALSE | FALSE | [2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method. | Streptococcus A,B,C,G |
| 513 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Daptomycin | Streptococcus groups A, B, C and G | NA | Note | Note | FALSE | FALSE | FALSE | [2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [A] Use an MIC method. | Streptococcus A,B,C,G |
| 514 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Fusidic acid | Streptococcus groups A, B, C and G | NA | IE | IE | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 515 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Fusidic acid | Streptococcus groups A, B, C and G | NA | IE | IE | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 516 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Nitrofurantoin (uncomplicated UTI only), S. agalactiae (group B streptococci) | Streptococcus groups A, B, C and G | NA | 64 | 64 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 517 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Nitrofurantoin (uncomplicated UTI only), S. agalactiae (group B streptococci) | Streptococcus groups A, B, C and G | 100 mcg | 15 | 15 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 518 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Rifampicin | Streptococcus groups A, B, C and G | NA | 0.06 | 0.5 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 519 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Rifampicin | Streptococcus groups A, B, C and G | 5 mcg | 21 | 15 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 520 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci) | Streptococcus groups A, B, C and G | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 521 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Trimethoprim (uncomplicated UTI only), S. agalactiae (group B streptococci) | Streptococcus groups A, B, C and G | 5 mcg | IP | IP | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 522 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | NA | Trimethoprim-sulfamethoxazole | Streptococcus groups A, B, C and G | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 523 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | NA | Trimethoprim-sulfamethoxazole | Streptococcus groups A, B, C and G | 1.25/23.75 mcg | 18 | 15 | FALSE | FALSE | FALSE | NA | Streptococcus A,B,C,G |
| 524 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (indications other than meningitis) | Streptococcus pneumoniae | NA | 0.06 | 2 | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 525 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (indications other than meningitis) | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 526 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (meningitis) | Streptococcus pneumoniae | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 527 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Benzylpenicillin (meningitis) | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 528 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ampicillin | Streptococcus pneumoniae | NA | 0.5 | 2 | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 529 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ampicillin | Streptococcus pneumoniae | 2 mcg | 22 | 16 | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 530 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ampicillin-sulbactam | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 531 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ampicillin-sulbactam | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 532 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin iv | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 533 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin iv | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 534 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin oral | Streptococcus pneumoniae | NA | 0.5 | 1 | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | S.pneumoniae |
| 535 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin oral | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | S.pneumoniae |
| 536 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid iv | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 537 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid iv | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 538 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid oral | Streptococcus pneumoniae | NA | 0.5 | 1 | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | S.pneumoniae |
| 539 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid oral | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | S.pneumoniae |
| 540 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Piperacillin | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 541 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Piperacillin | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 542 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Piperacillin-tazobactam | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 543 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Piperacillin-tazobactam | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4/B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 544 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Phenoxymethylpenicillin | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 545 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Phenoxymethylpenicillin | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 546 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Oxacillin (screen) | Streptococcus pneumoniae | 1 mcg | 20 | Note | FALSE | FALSE | FALSE | [D] For interpretation of the oxacillin disk screen, see flow chart below. For oxacillin non-susceptible isolates, always determine the MIC of benzylpenicillin. | S.pneumoniae |
| 547 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefaclor | Streptococcus pneumoniae | NA | 0.03 | 0.5 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 548 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefaclor | Streptococcus pneumoniae | 30 mcg | 50 | 28 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 549 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefepime | Streptococcus pneumoniae | NA | 1 | 2 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 550 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefepime | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 551 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefotaxime | Streptococcus pneumoniae | NA | 0.5 | 2 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 552 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefotaxime | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 553 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefpodoxime | Streptococcus pneumoniae | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 554 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefpodoxime | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 555 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ceftaroline | Streptococcus pneumoniae | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 556 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ceftaroline | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 557 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ceftobiprole | Streptococcus pneumoniae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 558 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ceftobiprole | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 559 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ceftriaxone | Streptococcus pneumoniae | NA | 0.5 | 2 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 560 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ceftriaxone | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 561 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefuroxime iv | Streptococcus pneumoniae | NA | 0.5 | 1 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 562 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefuroxime iv | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 563 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Cefuroxime oral | Streptococcus pneumoniae | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 564 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Cefuroxime oral | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 565 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Ertapenem | Streptococcus pneumoniae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 566 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Ertapenem | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 567 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Imipenem | Streptococcus pneumoniae | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 568 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Imipenem | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 569 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Meropenem (indications other than meningitis) | Streptococcus pneumoniae | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 570 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Meropenem (indications other than meningitis) | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 571 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Meropenem(meningitis) | Streptococcus pneumoniae | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC. | S.pneumoniae |
| 572 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Meropenem(meningitis) | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC. | S.pneumoniae |
| 573 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Meropenem-vaborbactam | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 574 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Meropenem-vaborbactam | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 575 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Levofloxacin | Streptococcus pneumoniae | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | S.pneumoniae |
| 576 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Levofloxacin | Streptococcus pneumoniae | 5 mcg | 16 | 16 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | S.pneumoniae |
| 577 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Moxifloxacin | Streptococcus pneumoniae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | S.pneumoniae |
| 578 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Moxifloxacin | Streptococcus pneumoniae | 5 mcg | 22 | 22 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | S.pneumoniae |
| 579 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Norfloxacin (screen) | Streptococcus pneumoniae | 10 mcg | 10 | Note | FALSE | FALSE | FALSE | [B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | S.pneumoniae |
| 580 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Dalbavancin | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 581 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Dalbavancin | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 582 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Oritavancin | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 583 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Oritavancin | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 584 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Teicoplanin | Streptococcus pneumoniae | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | S.pneumoniae |
| 585 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Teicoplanin | Streptococcus pneumoniae | 30 mcg | 17 | 17 | FALSE | FALSE | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | S.pneumoniae |
| 586 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Telavancin | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 587 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Telavancin | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 588 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Vancomycin | Streptococcus pneumoniae | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | S.pneumoniae |
| 589 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Vancomycin | Streptococcus pneumoniae | 5 mcg | 16 | 16 | FALSE | FALSE | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | S.pneumoniae |
| 590 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Azithromycin | Streptococcus pneumoniae | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 591 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Azithromycin | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 592 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Clarithromycin | Streptococcus pneumoniae | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 593 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Clarithromycin | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 594 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Erythromycin | Streptococcus pneumoniae | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 595 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Erythromycin | Streptococcus pneumoniae | 15 mcg | 22 | 19 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 596 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Roxithromycin | Streptococcus pneumoniae | NA | 0.5 | 1 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 597 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Roxithromycin | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 598 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Telithromycin | Streptococcus pneumoniae | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 599 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Telithromycin | Streptococcus pneumoniae | 15 mcg | 23 | 20 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 600 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Clindamycin | Streptococcus pneumoniae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | S.pneumoniae |
| 601 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Clindamycin | Streptococcus pneumoniae | 2 mcg | 19 | 19 | FALSE | FALSE | FALSE | [B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | S.pneumoniae |
| 602 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Doxycycline | Streptococcus pneumoniae | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 603 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Doxycycline | Streptococcus pneumoniae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 604 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Eravacycline | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 605 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Eravacycline | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 606 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Minocycline | Streptococcus pneumoniae | NA | 0.5 | 1 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 607 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Minocycline | Streptococcus pneumoniae | 30 mcg | 24 | 21 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 608 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Tetracycline | Streptococcus pneumoniae | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 609 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Tetracycline | Streptococcus pneumoniae | 30 mcg | 25 | 22 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 610 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Tigecycline | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 611 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Tigecycline | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 612 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Linezolid | Streptococcus pneumoniae | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 613 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Linezolid | Streptococcus pneumoniae | 10 mcg | 22 | 19 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 614 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Tedizolid | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 615 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Tedizolid | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 616 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Chloramphenicol | Streptococcus pneumoniae | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 617 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Chloramphenicol | Streptococcus pneumoniae | 30 mcg | 21 | 21 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 618 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Daptomycin | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 619 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Daptomycin | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 620 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Fosfomycin iv | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 621 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Fosfomycin iv | Streptococcus pneumoniae | NA | IE | IE | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 622 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Rifampicin | Streptococcus pneumoniae | NA | 0.06 | 0.5 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 623 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Rifampicin | Streptococcus pneumoniae | 5 mcg | 22 | 17 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 624 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | NA | Trimethoprim-sulfamethoxazole | Streptococcus pneumoniae | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 625 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | NA | Trimethoprim-sulfamethoxazole | Streptococcus pneumoniae | 1.25/23.75 mcg | 13 | 10 | FALSE | FALSE | FALSE | NA | S.pneumoniae |
| 626 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Benzylpenicillin | Viridans group streptococci | NA | 0.25 | 2 | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 627 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Benzylpenicillin | Viridans group streptococci | 1 unit | 18 | 12 | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 628 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Benzylpenicillin (screen) | Viridans group streptococci | 1 unit | 18 | Note | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 629 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ampicillin | Viridans group streptococci | NA | 0.5 | 2 | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 630 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ampicillin | Viridans group streptococci | 2 mcg | 21 | 15 | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 631 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ampicillin-sulbactam | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 632 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ampicillin-sulbactam | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 633 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Amoxicillin | Viridans group streptococci | NA | 0.5 | 2 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 634 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Amoxicillin | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 635 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Amoxicillin-clavulanic acid | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 636 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Amoxicillin-clavulanic acid | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 637 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Piperacillin | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 638 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Piperacillin | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 639 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Piperacillin-tazobactam | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 640 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Piperacillin-tazobactam | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [1/B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 641 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ticarcillin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 642 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ticarcillin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 643 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ticarcillin-clavulanic acid | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 644 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ticarcillin-clavulanic acid | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 645 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Phenoxymethylpenicillin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 646 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Phenoxymethylpenicillin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 647 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefazolin | Viridans group streptococci | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 648 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefazolin | Viridans group streptococci | 30 mcg | IP | IP | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 649 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefepime | Viridans group streptococci | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 650 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefepime | Viridans group streptococci | 30 mcg | 25 | 25 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 651 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefotaxime | Viridans group streptococci | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 652 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefotaxime | Viridans group streptococci | 5 mcg | 23 | 23 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 653 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ceftolozane-tazobactam, S. anginosus group | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 654 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ceftolozane-tazobactam, S. anginosus group | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 655 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ceftriaxone | Viridans group streptococci | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 656 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ceftriaxone | Viridans group streptococci | 30 mcg | 27 | 27 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 657 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Cefuroxime iv | Viridans group streptococci | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 658 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Cefuroxime iv | Viridans group streptococci | 30 mcg | 26 | 26 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 659 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Ertapenem | Viridans group streptococci | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 660 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Ertapenem | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 661 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Imipenem | Viridans group streptococci | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 662 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Imipenem | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 663 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Meropenem | Viridans group streptococci | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 664 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Meropenem | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 665 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Meropenem-vaborbactam | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 666 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Meropenem-vaborbactam | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 667 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Levofloxacin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 668 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Levofloxacin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 669 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Moxifloxacin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 670 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Moxifloxacin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 671 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Amikacin | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 672 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Gentamicin (test for high-level aminoglycoside resistance) | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 673 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Netilmicin | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 674 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Tobramycin | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 675 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Dalbavancin, S. anginosus group | Viridans group streptococci | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | Viridans group streptococci |
| 676 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Dalbavancin, S. anginosus group | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | Viridans group streptococci |
| 677 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Oritavancin, S. anginosus group | Viridans group streptococci | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | Viridans group streptococci |
| 678 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Oritavancin, S. anginosus group | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | Viridans group streptococci |
| 679 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Teicoplanin | Viridans group streptococci | NA | 2 | 2 | FALSE | FALSE | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | Viridans group streptococci |
| 680 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Teicoplanin | Viridans group streptococci | 30 mcg | 16 | 16 | FALSE | FALSE | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | Viridans group streptococci |
| 681 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Telavancin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 682 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Telavancin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 683 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Vancomycin | Viridans group streptococci | NA | 2 | 2 | FALSE | FALSE | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | Viridans group streptococci |
| 684 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Vancomycin | Viridans group streptococci | 5 mcg | 15 | 15 | FALSE | FALSE | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | Viridans group streptococci |
| 685 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Azithromycin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 686 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Azithromycin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 687 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Clarithromycin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 688 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Clarithromycin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 689 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Erythromycin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 690 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Erythromycin | Viridans group streptococci | 15 mcg | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 691 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Roxithromycin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 692 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Roxithromycin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 693 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Telithromycin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 694 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Telithromycin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 695 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Clindamycin | Viridans group streptococci | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | Viridans group streptococci |
| 696 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Clindamycin | Viridans group streptococci | 2 mcg | 19 | 19 | FALSE | FALSE | FALSE | [A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | Viridans group streptococci |
| 697 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Quinupristin-dalfopristin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 698 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Quinupristin-dalfopristin | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 699 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Eravacycline | Viridans group streptococci | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 700 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Eravacycline | Viridans group streptococci | IP mcg | IP | IP | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 701 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Tigecycline | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 702 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Tigecycline | Viridans group streptococci | NA | IE | IE | FALSE | FALSE | FALSE | NA | Viridans group streptococci |
| 703 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Viridans group streptococci | NA | Tedizolid, S. anginosus group | Viridans group streptococci | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] Perform an MIC test. | Viridans group streptococci |
| 704 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Viridans group streptococci | NA | Tedizolid, S. anginosus group | Viridans group streptococci | NA | Note | Note | FALSE | FALSE | FALSE | [A] Perform an MIC test. | Viridans group streptococci |
| 705 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Benzylpenicillin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 706 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Benzylpenicillin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 707 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Benzylpenicillin (screen) | Haemophilus influenzae | 1 unit | 12 | Note | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 708 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ampicillin | Haemophilus influenzae | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 709 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ampicillin | Haemophilus influenzae | 2 mcg | 16 | 16 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 710 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ampicillin-sulbactam | Haemophilus influenzae | NA | 1 | 1 | FALSE | FALSE | FALSE | [4/C] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 711 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ampicillin-sulbactam | Haemophilus influenzae | 10/10 mcg | Note | Note | FALSE | FALSE | FALSE | [4/C] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 712 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin iv | Haemophilus influenzae | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | H.influenzae |
| 713 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin iv | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | H.influenzae |
| 714 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin oral | Haemophilus influenzae | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | H.influenzae |
| 715 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin oral | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | H.influenzae |
| 716 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid iv | Haemophilus influenzae | NA | 2 | 2 | FALSE | FALSE | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 717 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid iv | Haemophilus influenzae | 2/1 mcg | 15 | 15 | FALSE | FALSE | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 718 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid oral | Haemophilus influenzae | NA | 2 | 2 | FALSE | FALSE | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 719 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid oral | Haemophilus influenzae | 2/1 mcg | 15 | 15 | FALSE | FALSE | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 720 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Piperacillin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 721 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Piperacillin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 722 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Piperacillin-tazobactam | Haemophilus influenzae | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 723 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Piperacillin-tazobactam | Haemophilus influenzae | 30/6 mcg | 27 | 27 | FALSE | FALSE | FALSE | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 724 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ticarcillin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 725 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ticarcillin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 726 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ticarcillin-clavulanic acid | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 727 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ticarcillin-clavulanic acid | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 728 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Temocillin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 729 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Temocillin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 730 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Phenoxymethylpenicillin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 731 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Phenoxymethylpenicillin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 732 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefepime | Haemophilus influenzae | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | H.influenzae |
| 733 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefepime | Haemophilus influenzae | 30 mcg | 28 | 28 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | H.influenzae |
| 734 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefixime | Haemophilus influenzae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 735 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefixime | Haemophilus influenzae | 5 mcg | 26 | 26 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 736 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefotaxime | Haemophilus influenzae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 737 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefotaxime | Haemophilus influenzae | 5 mcg | 27 | 27 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 738 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefpodoxime | Haemophilus influenzae | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | H.influenzae |
| 739 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefpodoxime | Haemophilus influenzae | 10 mcg | 26 | 26 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | H.influenzae |
| 740 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftaroline | Haemophilus influenzae | NA | 0.03 | 0.03 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 741 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftaroline | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 742 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftibuten | Haemophilus influenzae | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 743 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftibuten | Haemophilus influenzae | 30 mcg | 25 | 25 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 744 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftobiprole | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 745 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftobiprole | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 746 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftolozane-tazobactam | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 747 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftolozane-tazobactam | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 748 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ceftriaxone | Haemophilus influenzae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 749 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ceftriaxone | Haemophilus influenzae | 30 mcg | 32 | 32 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 750 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefuroxime iv | Haemophilus influenzae | NA | 1 | 2 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 751 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefuroxime iv | Haemophilus influenzae | 30 mcg | 27 | 25 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 752 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Cefuroxime oral | Haemophilus influenzae | NA | 0.125 | 1 | FALSE | FALSE | FALSE | NA | H.influenzae |
| 753 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Cefuroxime oral | Haemophilus influenzae | 30 mcg | 50 | 27 | FALSE | FALSE | FALSE | NA | H.influenzae |
| 754 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ertapenem | Haemophilus influenzae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 755 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ertapenem | Haemophilus influenzae | 10 mcg | 23 | 23 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 756 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Imipenem | Haemophilus influenzae | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | H.influenzae |
| 757 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Imipenem | Haemophilus influenzae | 10 mcg | 20 | 20 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | H.influenzae |
| 758 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Meropenem (indications other than meningitis) | Haemophilus influenzae | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 759 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Meropenem (indications other than meningitis) | Haemophilus influenzae | 10 mcg | 20 | 20 | FALSE | FALSE | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 760 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Meropenem(meningitis) | Haemophilus influenzae | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [C] For use in meningitis determine the meropenem MIC value. | H.influenzae |
| 761 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Meropenem(meningitis) | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [C] For use in meningitis determine the meropenem MIC value. | H.influenzae |
| 762 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Meropenem-vaborbactam | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 763 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Meropenem-vaborbactam | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 764 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Aztreonam | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 765 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Aztreonam | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 766 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ciprofloxacin | Haemophilus influenzae | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 767 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ciprofloxacin | Haemophilus influenzae | 5 mcg | 30 | 30 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 768 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Levofloxacin | Haemophilus influenzae | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 769 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Levofloxacin | Haemophilus influenzae | 5 mcg | 30 | 30 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 770 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Moxifloxacin | Haemophilus influenzae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 771 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Moxifloxacin | Haemophilus influenzae | 5 mcg | 28 | 28 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 772 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Nalidixic acid (screen) | Haemophilus influenzae | 30 mcg | 23 | Note | FALSE | FALSE | FALSE | [B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. | H.influenzae |
| 773 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Ofloxacin | Haemophilus influenzae | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 774 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Ofloxacin | Haemophilus influenzae | 5 mcg | 30 | 30 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | H.influenzae |
| 775 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Amikacin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 776 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Amikacin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 777 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Gentamicin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 778 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Gentamicin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 779 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Netilmicin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 780 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Netilmicin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 781 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Tobramycin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 782 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Tobramycin | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 783 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Azithromycin | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 784 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Azithromycin | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 785 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Clarithromycin | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 786 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Clarithromycin | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 787 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Erythromycin | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 788 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Erythromycin | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 789 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Roxithromycin | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 790 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Roxithromycin | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 791 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Telithromycin | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 792 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Telithromycin | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 793 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Doxycycline | Haemophilus influenzae | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 794 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Doxycycline | Haemophilus influenzae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 795 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Eravacycline | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 796 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Eravacycline | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 797 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Minocycline | Haemophilus influenzae | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 798 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Minocycline | Haemophilus influenzae | 30 mcg | 24 | 21 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 799 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Tetracycline | Haemophilus influenzae | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 800 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Tetracycline | Haemophilus influenzae | 30 mcg | 25 | 22 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 801 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Tigecycline | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 802 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Tigecycline | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 803 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Chloramphenicol | Haemophilus influenzae | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | H.influenzae |
| 804 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Chloramphenicol | Haemophilus influenzae | 30 mcg | 28 | 28 | FALSE | FALSE | FALSE | NA | H.influenzae |
| 805 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Fosfomycin iv | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 806 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Fosfomycin iv | Haemophilus influenzae | NA | IE | IE | FALSE | FALSE | FALSE | NA | H.influenzae |
| 807 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Rifampicin (for prophylaxis only) | Haemophilus influenzae | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | H.influenzae |
| 808 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Rifampicin (for prophylaxis only) | Haemophilus influenzae | 5 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | H.influenzae |
| 809 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Haemophilus influenzae | NA | Trimethoprim-sulfamethoxazole | Haemophilus influenzae | NA | 0.5 | 1 | FALSE | FALSE | FALSE | NA | H.influenzae |
| 810 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Haemophilus influenzae | NA | Trimethoprim-sulfamethoxazole | Haemophilus influenzae | 1.25/23.75 mcg | 23 | 20 | FALSE | FALSE | FALSE | NA | H.influenzae |
| 811 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ampicillin-sulbactam | Moraxella catarrhalis | NA | 1 | 1 | FALSE | FALSE | FALSE | [3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | M.catarrhalis |
| 812 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ampicillin-sulbactam | Moraxella catarrhalis | NA | Note | Note | FALSE | FALSE | FALSE | [3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | M.catarrhalis |
| 813 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Amoxicillin-clavulanic acid | Moraxella catarrhalis | NA | 1 | 1 | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | M.catarrhalis |
| 814 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Amoxicillin-clavulanic acid | Moraxella catarrhalis | 2/1 mcg | 19 | 19 | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | M.catarrhalis |
| 815 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Piperacillin-tazobactam | Moraxella catarrhalis | NA | Note | Note | FALSE | FALSE | FALSE | [3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 816 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Piperacillin-tazobactam | Moraxella catarrhalis | NA | Note | Note | FALSE | FALSE | FALSE | [3/A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 817 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ticarcillin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 818 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ticarcillin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 819 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ticarcillin-clavulanic acid | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 820 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ticarcillin-clavulanic acid | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 821 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Temocillin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 822 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Temocillin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 823 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefepime | Moraxella catarrhalis | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 824 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefepime | Moraxella catarrhalis | 30 mcg | 20 | 20 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 825 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefixime | Moraxella catarrhalis | NA | 0.5 | 1 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 826 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefixime | Moraxella catarrhalis | 5 mcg | 21 | 18 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 827 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefotaxime | Moraxella catarrhalis | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 828 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefotaxime | Moraxella catarrhalis | 5 mcg | 20 | 17 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 829 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefpodoxime | Moraxella catarrhalis | NA | IP | IP | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 830 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefpodoxime | Moraxella catarrhalis | 10 mcg | IP | IP | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 831 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ceftaroline | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 832 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ceftaroline | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 833 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ceftibuten | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 834 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ceftibuten | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 835 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ceftobiprole | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 836 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ceftobiprole | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 837 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ceftolozane-tazobactam | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 838 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ceftolozane-tazobactam | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 839 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ceftriaxone | Moraxella catarrhalis | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 840 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ceftriaxone | Moraxella catarrhalis | 30 mcg | 24 | 21 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 841 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefuroxime iv | Moraxella catarrhalis | NA | 4 | 8 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 842 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefuroxime iv | Moraxella catarrhalis | 30 mcg | 21 | 18 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 843 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Cefuroxime oral | Moraxella catarrhalis | NA | 0.125 | 4 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 844 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Cefuroxime oral | Moraxella catarrhalis | 30 mcg | 50 | 21 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 845 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ertapenem | Moraxella catarrhalis | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 846 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ertapenem | Moraxella catarrhalis | 10 mcg | 29 | 29 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 847 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Imipenem | Moraxella catarrhalis | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 848 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Imipenem | Moraxella catarrhalis | 10 mcg | 29 | 29 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 849 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Meropenem | Moraxella catarrhalis | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 850 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Meropenem | Moraxella catarrhalis | 10 mcg | 33 | 33 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 851 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Meropenem-vaborbactam | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 852 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Meropenem-vaborbactam | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 853 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Aztreonam | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 854 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Aztreonam | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 855 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ciprofloxacin | Moraxella catarrhalis | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 856 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ciprofloxacin | Moraxella catarrhalis | 5 mcg | 31 | 31 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 857 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Levofloxacin | Moraxella catarrhalis | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 858 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Levofloxacin | Moraxella catarrhalis | 5 mcg | 29 | 29 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 859 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Moxifloxacin | Moraxella catarrhalis | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 860 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Moxifloxacin | Moraxella catarrhalis | 5 mcg | 26 | 26 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 861 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Nalidixic acid (screen) | Moraxella catarrhalis | 30 mcg | 23 | Note | FALSE | FALSE | FALSE | [B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. | M.catarrhalis |
| 862 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Ofloxacin | Moraxella catarrhalis | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 863 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Ofloxacin | Moraxella catarrhalis | 5 mcg | 28 | 28 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | M.catarrhalis |
| 864 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Amikacin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 865 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Amikacin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 866 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Gentamicin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 867 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Gentamicin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 868 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Netilmicin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 869 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Netilmicin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 870 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Tobramycin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 871 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Tobramycin | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 872 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Azithromycin | Moraxella catarrhalis | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 873 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Azithromycin | Moraxella catarrhalis | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 874 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Clarithromycin | Moraxella catarrhalis | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 875 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Clarithromycin | Moraxella catarrhalis | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 876 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Erythromycin | Moraxella catarrhalis | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 877 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Erythromycin | Moraxella catarrhalis | 15 mcg | 23 | 20 | FALSE | FALSE | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 878 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Roxithromycin | Moraxella catarrhalis | NA | 0.5 | 1 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 879 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Roxithromycin | Moraxella catarrhalis | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 880 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Telithromycin | Moraxella catarrhalis | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 881 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Telithromycin | Moraxella catarrhalis | 15 mcg | 23 | 20 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 882 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Doxycycline | Moraxella catarrhalis | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 883 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Doxycycline | Moraxella catarrhalis | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 884 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Eravacycline | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 885 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Eravacycline | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 886 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Minocycline | Moraxella catarrhalis | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 887 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Minocycline | Moraxella catarrhalis | 30 mcg | 25 | 22 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 888 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Tetracycline | Moraxella catarrhalis | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 889 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Tetracycline | Moraxella catarrhalis | 30 mcg | 28 | 25 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 890 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Tigecycline | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 891 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Tigecycline | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 892 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Chloramphenicol | Moraxella catarrhalis | NA | 2 | 2 | FALSE | FALSE | FALSE | [1/A] Breakpoints relate to topical use only. | M.catarrhalis |
| 893 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Chloramphenicol | Moraxella catarrhalis | 30 mcg | 30 | 30 | FALSE | FALSE | FALSE | [1/A] Breakpoints relate to topical use only. | M.catarrhalis |
| 894 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Fosfomycin iv | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 895 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Fosfomycin iv | Moraxella catarrhalis | NA | IE | IE | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 896 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Moraxella catarrhalis | NA | Trimethoprim-sulfamethoxazole | Moraxella catarrhalis | NA | 0.5 | 1 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 897 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Moraxella catarrhalis | NA | Trimethoprim-sulfamethoxazole | Moraxella catarrhalis | 1.25/23.75 mcg | 18 | 15 | FALSE | FALSE | FALSE | NA | M.catarrhalis |
| 898 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Benzylpenicillin | Neisseria gonorrhoeae | NA | 0.06 | 1 | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 899 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ampicillin | Neisseria gonorrhoeae | NA | Note | Note | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 900 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ampicillin-sulbactam | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 901 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Amoxicillin | Neisseria gonorrhoeae | NA | Note | Note | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 902 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Amoxicillin-clavulanic acid | Neisseria gonorrhoeae | NA | Note | Note | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 903 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Temocillin | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 904 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Cefixime | Neisseria gonorrhoeae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 905 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Cefotaxime | Neisseria gonorrhoeae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 906 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ceftriaxone | Neisseria gonorrhoeae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 907 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ertapenem | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 908 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Imipenem | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 909 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Meropenem | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 910 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Meropenem-vaborbactam | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 911 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Aztreonam | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 912 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ciprofloxacin | Neisseria gonorrhoeae | NA | 0.03 | 0.06 | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 913 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Levofloxacin | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 914 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Moxifloxacin | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 915 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Ofloxacin | Neisseria gonorrhoeae | NA | 0.125 | 0.25 | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 916 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Azithromycin | Neisseria gonorrhoeae | NA | Note | Note | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 917 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Doxycycline | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 918 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Eravacycline | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 919 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Minocycline | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 920 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Tetracycline | Neisseria gonorrhoeae | NA | 0.5 | 1 | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 921 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Tigecycline | Neisseria gonorrhoeae | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 922 | NA | NA | human | human | MIC | NA | Neisseria gonorrhoeae | NA | Spectinomycin | Neisseria gonorrhoeae | NA | 64 | 64 | FALSE | FALSE | FALSE | NA | N.gonorrhoeae |
| 923 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Benzylpenicillin | Neisseria meningitidis | NA | 0.06 | 0.25 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 924 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Ampicillin | Neisseria meningitidis | NA | 0.125 | 1 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 925 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Ampicillin-sulbactam | Neisseria meningitidis | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 926 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Amoxicillin | Neisseria meningitidis | NA | 0.125 | 1 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 927 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Cefotaxime | Neisseria meningitidis | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 928 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Ceftriaxone | Neisseria meningitidis | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 929 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Meropenem(meningitis) | Neisseria meningitidis | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 930 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Meropenem-vaborbactam | Neisseria meningitidis | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 931 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Ciprofloxacin | Neisseria meningitidis | NA | 0.03 | 0.03 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 932 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Levofloxacin | Neisseria meningitidis | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 933 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Moxifloxacin | Neisseria meningitidis | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 934 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Ofloxacin | Neisseria meningitidis | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 935 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Eravacycline | Neisseria meningitidis | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 936 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Minocycline | Neisseria meningitidis | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 937 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Tetracycline | Neisseria meningitidis | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 938 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Tigecycline | Neisseria meningitidis | NA | IE | IE | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 939 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Chloramphenicol | Neisseria meningitidis | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 940 | NA | NA | human | human | MIC | NA | Neisseria meningitidis | NA | Rifampicin | Neisseria meningitidis | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | N.meningitidis |
| 941 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Benzylpenicillin | Gram-positive anaerobes except Clostridioides difficile | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 942 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ampicillin | Gram-positive anaerobes except Clostridioides difficile | NA | 4 | 8 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 943 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ampicillin-sulbactam | Gram-positive anaerobes except Clostridioides difficile | NA | 4 | 8 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 944 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Amoxicillin | Gram-positive anaerobes except Clostridioides difficile | NA | 4 | 8 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 945 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Amoxicillin-clavulanic acid | Gram-positive anaerobes except Clostridioides difficile | NA | 4 | 8 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 946 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Piperacillin | Gram-positive anaerobes except Clostridioides difficile | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 947 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Piperacillin-tazobactam | Gram-positive anaerobes except Clostridioides difficile | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 948 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ticarcillin | Gram-positive anaerobes except Clostridioides difficile | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 949 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ticarcillin-clavulanic acid | Gram-positive anaerobes except Clostridioides difficile | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 950 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Phenoxymethylpenicillin | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 951 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Cefoxitin | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 952 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ceftolozane-tazobactam | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 953 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Ertapenem | Gram-positive anaerobes except Clostridioides difficile | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 954 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Imipenem | Gram-positive anaerobes except Clostridioides difficile | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 955 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Meropenem | Gram-positive anaerobes except Clostridioides difficile | NA | 2 | 8 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 956 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Meropenem-vaborbactam | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 957 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Moxifloxacin | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 958 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Dalbavancin | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 959 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Oritavancin | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 960 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Teicoplanin | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 961 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Telavancin | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 962 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Vancomycin | Gram-positive anaerobes except Clostridioides difficile | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 963 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Erythromycin | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 964 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Clindamycin | Gram-positive anaerobes except Clostridioides difficile | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 965 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Doxycycline | Gram-positive anaerobes except Clostridioides difficile | NA | Note | Note | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 966 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Eravacycline | Gram-positive anaerobes except Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 967 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Minocycline | Gram-positive anaerobes except Clostridioides difficile | NA | Note | Note | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 968 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Tetracycline | Gram-positive anaerobes except Clostridioides difficile | NA | Note | Note | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 969 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Tigecycline | Gram-positive anaerobes except Clostridioides difficile | NA | Note | Note | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 970 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Chloramphenicol | Gram-positive anaerobes except Clostridioides difficile | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 971 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Gram-positive anaerobes except Clostridioides difficile | NA | Metronidazole | Gram-positive anaerobes except Clostridioides difficile | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Anaerobes, Grampositive |
| 972 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Clostridioides difficile | NA | Vancomycin | Clostridioides difficile | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | C.difficile |
| 973 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Clostridioides difficile | NA | Fidaxomicin | Clostridioides difficile | NA | IE | IE | FALSE | FALSE | FALSE | NA | C.difficile |
| 974 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Clostridioides difficile | NA | Metronidazole | Clostridioides difficile | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | C.difficile |
| 975 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Benzylpenicillin | Gram-negative anaerobes | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 976 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Ampicillin | Gram-negative anaerobes | NA | 0.5 | 2 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 977 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Ampicillin-sulbactam | Gram-negative anaerobes | NA | 4 | 8 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 978 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Amoxicillin | Gram-negative anaerobes | NA | 0.5 | 2 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 979 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Amoxicillin-clavulanic acid | Gram-negative anaerobes | NA | 4 | 8 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 980 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Piperacillin | Gram-negative anaerobes | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 981 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Piperacillin-tazobactam | Gram-negative anaerobes | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 982 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Ticarcillin | Gram-negative anaerobes | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 983 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Ticarcillin-clavulanic acid | Gram-negative anaerobes | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 984 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Phenoxymethylpenicillin | Gram-negative anaerobes | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 985 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Cefoxitin | Gram-negative anaerobes | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 986 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Ceftolozane-tazobactam | Gram-negative anaerobes | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 987 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Ertapenem | Gram-negative anaerobes | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 988 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Imipenem | Gram-negative anaerobes | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 989 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Meropenem | Gram-negative anaerobes | NA | 2 | 8 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 990 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Meropenem-vaborbactam | Gram-negative anaerobes | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 991 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Moxifloxacin | Gram-negative anaerobes | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 992 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Erythromycin | Gram-negative anaerobes | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 993 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Clindamycin | Gram-negative anaerobes | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 994 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Doxycycline | Gram-negative anaerobes | NA | Note | Note | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 995 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Eravacycline | Gram-negative anaerobes | NA | IE | IE | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 996 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Minocycline | Gram-negative anaerobes | NA | Note | Note | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 997 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Tetracycline | Gram-negative anaerobes | NA | Note | Note | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 998 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Tigecycline | Gram-negative anaerobes | NA | Note | Note | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 999 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Chloramphenicol | Gram-negative anaerobes | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 1000 | NA | NA | human | human | MIC | NA | Gram-negative anaerobes | NA | Metronidazole | Gram-negative anaerobes | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Anaerobes, Gramnegative |
| 1001 | NA | NA | human | human | MIC | NA | Helicobacter pylori | NA | Amoxicillin | Helicobacter pylori | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | H.pylori |
| 1002 | NA | NA | human | human | MIC | NA | Helicobacter pylori | NA | Levofloxacin | Helicobacter pylori | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | H.pylori |
| 1003 | NA | NA | human | human | MIC | NA | Helicobacter pylori | NA | Clarithromycin | Helicobacter pylori | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | H.pylori |
| 1004 | NA | NA | human | human | MIC | NA | Helicobacter pylori | NA | Tetracycline | Helicobacter pylori | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | H.pylori |
| 1005 | NA | NA | human | human | MIC | NA | Helicobacter pylori | NA | Metronidazole | Helicobacter pylori | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | H.pylori |
| 1006 | NA | NA | human | human | MIC | NA | Helicobacter pylori | NA | Rifampicin | Helicobacter pylori | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | H.pylori |
| 1007 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Listeria monocytogenes | NA | Benzylpenicillin | Listeria monocytogenes | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | L.monocytogenes |
| 1008 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Listeria monocytogenes | NA | Benzylpenicillin | Listeria monocytogenes | 1 unit | 13 | 13 | FALSE | FALSE | FALSE | NA | L.monocytogenes |
| 1009 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Listeria monocytogenes | NA | Ampicillin | Listeria monocytogenes | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | L.monocytogenes |
| 1010 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Listeria monocytogenes | NA | Ampicillin | Listeria monocytogenes | 2 mcg | 16 | 16 | FALSE | FALSE | FALSE | NA | L.monocytogenes |
| 1011 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Listeria monocytogenes | NA | Meropenem | Listeria monocytogenes | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | L.monocytogenes |
| 1012 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Listeria monocytogenes | NA | Meropenem | Listeria monocytogenes | 10 mcg | 26 | 26 | FALSE | FALSE | FALSE | NA | L.monocytogenes |
| 1013 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Listeria monocytogenes | NA | Erythromycin | Listeria monocytogenes | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | L.monocytogenes |
| 1014 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Listeria monocytogenes | NA | Erythromycin | Listeria monocytogenes | 15 mcg | 25 | 25 | FALSE | FALSE | FALSE | NA | L.monocytogenes |
| 1015 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Listeria monocytogenes | NA | Trimethoprim-sulfamethoxazole | Listeria monocytogenes | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | NA | L.monocytogenes |
| 1016 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Listeria monocytogenes | NA | Trimethoprim-sulfamethoxazole | Listeria monocytogenes | 1.25/23.75 mcg | 29 | 29 | FALSE | FALSE | FALSE | NA | L.monocytogenes |
| 1017 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Benzylpenicillin | Pasteurella multocida | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | P.multocida |
| 1018 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Benzylpenicillin | Pasteurella multocida | 1 unit | 17 | 17 | FALSE | FALSE | FALSE | NA | P.multocida |
| 1019 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Ampicillin | Pasteurella multocida | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] Infer susceptibility from benzylpenicillin susceptibility. | P.multocida |
| 1020 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Ampicillin | Pasteurella multocida | NA | Note | Note | FALSE | FALSE | FALSE | [A] Infer susceptibility from benzylpenicillin susceptibility. | P.multocida |
| 1021 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Amoxicillin | Pasteurella multocida | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] Infer susceptibility from benzylpenicillin susceptibility. | P.multocida |
| 1022 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Amoxicillin | Pasteurella multocida | NA | Note | Note | FALSE | FALSE | FALSE | [A] Infer susceptibility from benzylpenicillin susceptibility. | P.multocida |
| 1023 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Amoxicillin-clavulanic acid | Pasteurella multocida | NA | 1 | 1 | FALSE | FALSE | FALSE | [1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | P.multocida |
| 1024 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Amoxicillin-clavulanic acid | Pasteurella multocida | 2/1 mcg | 15 | 15 | FALSE | FALSE | FALSE | [1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | P.multocida |
| 1025 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Cefotaxime | Pasteurella multocida | NA | 0.03 | 0.03 | FALSE | FALSE | FALSE | NA | P.multocida |
| 1026 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Cefotaxime | Pasteurella multocida | 5 mcg | 26 | 26 | FALSE | FALSE | FALSE | NA | P.multocida |
| 1027 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Ciprofloxacin | Pasteurella multocida | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | P.multocida |
| 1028 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Ciprofloxacin | Pasteurella multocida | 5 mcg | 27 | 27 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | P.multocida |
| 1029 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Levofloxacin | Pasteurella multocida | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | P.multocida |
| 1030 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Levofloxacin | Pasteurella multocida | 5 mcg | 27 | 27 | FALSE | FALSE | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | P.multocida |
| 1031 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Nalidixic acid (screen) | Pasteurella multocida | 30 mcg | 23 | Note | FALSE | FALSE | FALSE | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. | P.multocida |
| 1032 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Doxycycline | Pasteurella multocida | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] Susceptibility inferred from tetracycline screen test. | P.multocida |
| 1033 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Doxycycline | Pasteurella multocida | NA | Note | Note | FALSE | FALSE | FALSE | [A] Susceptibility inferred from tetracycline screen test. | P.multocida |
| 1034 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Tetracycline (screen) | Pasteurella multocida | 30 mcg | 24 | 24 | FALSE | FALSE | FALSE | [A] Susceptibility inferred from tetracycline screen test. | P.multocida |
| 1035 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Pasteurella multocida | NA | Trimethoprim-sulfamethoxazole | Pasteurella multocida | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | P.multocida |
| 1036 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Pasteurella multocida | NA | Trimethoprim-sulfamethoxazole | Pasteurella multocida | 1.25/23.75 mcg | 23 | 23 | FALSE | FALSE | FALSE | NA | P.multocida |
| 1037 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Ciprofloxacin | Campylobacter jejuni and coli | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | C.jejuni_C.coli |
| 1038 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Ciprofloxacin | Campylobacter jejuni and coli | 5 mcg | 26 | 26 | FALSE | FALSE | FALSE | NA | C.jejuni_C.coli |
| 1039 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Azithromycin | Campylobacter jejuni and coli | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 1040 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Azithromycin | Campylobacter jejuni and coli | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 1041 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Clarithromycin | Campylobacter jejuni and coli | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 1042 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Clarithromycin | Campylobacter jejuni and coli | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 1043 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Erythromycin,C. jejuni | Campylobacter jejuni and coli | NA | 4 | 4 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 1044 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Erythromycin,C. jejuni | Campylobacter jejuni and coli | 15 mcg | 20 | 20 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 1045 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Erythromycin,C. coli | Campylobacter jejuni and coli | NA | 8 | 8 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 1046 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Erythromycin,C. coli | Campylobacter jejuni and coli | 15 mcg | 24 | 24 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin. | C.jejuni_C.coli |
| 1047 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Doxycycline | Campylobacter jejuni and coli | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Tetracycline can be used to determine susceptibility to doxycycline. | C.jejuni_C.coli |
| 1048 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Doxycycline | Campylobacter jejuni and coli | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Tetracycline can be used to determine susceptibility to doxycycline. | C.jejuni_C.coli |
| 1049 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Campylobacter jejuni and coli | NA | Tetracycline | Campylobacter jejuni and coli | NA | 2 | 2 | FALSE | FALSE | FALSE | [1/A] Tetracycline can be used to determine susceptibility to doxycycline. | C.jejuni_C.coli |
| 1050 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Campylobacter jejuni and coli | NA | Tetracycline | Campylobacter jejuni and coli | 30 mcg | 30 | 30 | FALSE | FALSE | FALSE | [1/A] Tetracycline can be used to determine susceptibility to doxycycline. | C.jejuni_C.coli |
| 1051 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Benzylpenicillin | Corynebacterium spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1052 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Benzylpenicillin | Corynebacterium spp. | 1 unit | 29 | 29 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1053 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Ciprofloxacin | Corynebacterium spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1054 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Ciprofloxacin | Corynebacterium spp. | 5 mcg | 25 | 25 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1055 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Moxifloxacin | Corynebacterium spp. | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1056 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Moxifloxacin | Corynebacterium spp. | 5 mcg | 25 | 25 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1057 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Gentamicin | Corynebacterium spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1058 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Gentamicin | Corynebacterium spp. | 10 mcg | 23 | 23 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1059 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Vancomycin | Corynebacterium spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | Corynebacterium |
| 1060 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Vancomycin | Corynebacterium spp. | 5 mcg | 17 | 17 | FALSE | FALSE | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | Corynebacterium |
| 1061 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Erythromycin | Corynebacterium spp. | NA | IP | IP | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1062 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Erythromycin | Corynebacterium spp. | 15 mcg | IP | IP | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1063 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Clindamycin | Corynebacterium spp. | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1064 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Clindamycin | Corynebacterium spp. | 2 mcg | 20 | 20 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1065 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Tetracycline | Corynebacterium spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1066 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Tetracycline | Corynebacterium spp. | 30 mcg | 24 | 24 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1067 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Linezolid | Corynebacterium spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1068 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Linezolid | Corynebacterium spp. | 10 mcg | 25 | 25 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1069 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Corynebacterium spp. | NA | Rifampicin | Corynebacterium spp. | NA | 0.06 | 0.5 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1070 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Corynebacterium spp. | NA | Rifampicin | Corynebacterium spp. | 5 mcg | 30 | 25 | FALSE | FALSE | FALSE | NA | Corynebacterium |
| 1071 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Benzylpenicillin | Aerococcus sanguinicola and urinae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | A.sanguinicola_A.urinae |
| 1072 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Benzylpenicillin | Aerococcus sanguinicola and urinae | 1 unit | 21 | 21 | FALSE | FALSE | FALSE | NA | A.sanguinicola_A.urinae |
| 1073 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Ampicillin | Aerococcus sanguinicola and urinae | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | A.sanguinicola_A.urinae |
| 1074 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Ampicillin | Aerococcus sanguinicola and urinae | 2 mcg | 26 | 26 | FALSE | FALSE | FALSE | NA | A.sanguinicola_A.urinae |
| 1075 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Amoxicillin | Aerococcus sanguinicola and urinae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Infer susceptibility from ampicillin susceptibility. | A.sanguinicola_A.urinae |
| 1076 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Amoxicillin | Aerococcus sanguinicola and urinae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Infer susceptibility from ampicillin susceptibility. | A.sanguinicola_A.urinae |
| 1077 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Meropenem | Aerococcus sanguinicola and urinae | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | A.sanguinicola_A.urinae |
| 1078 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Meropenem | Aerococcus sanguinicola and urinae | 10 mcg | 31 | 31 | FALSE | FALSE | FALSE | NA | A.sanguinicola_A.urinae |
| 1079 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Ciprofloxacin (uncomplicated UTI only) | Aerococcus sanguinicola and urinae | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Susceptibility can be inferred from norfloxacin susceptibility. See Note | A.sanguinicola_A.urinae |
| 1080 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Ciprofloxacin (uncomplicated UTI only) | Aerococcus sanguinicola and urinae | 5 mcg | 21 | 21 | FALSE | FALSE | FALSE | [A] Susceptibility can be inferred from norfloxacin susceptibility. See Note | A.sanguinicola_A.urinae |
| 1081 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Levofloxacin (uncomplicated UTI only) | Aerococcus sanguinicola and urinae | NA | 2 | 2 | FALSE | FALSE | FALSE | [1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note | A.sanguinicola_A.urinae |
| 1082 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Levofloxacin (uncomplicated UTI only) | Aerococcus sanguinicola and urinae | 5 mcg | Note | Note | FALSE | FALSE | FALSE | [1] Susceptibility can be inferred from ciprofloxacin susceptibility. | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note | A.sanguinicola_A.urinae |
| 1083 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Norfloxacin (screen) | Aerococcus sanguinicola and urinae | 10 mcg | 17 | 17 | FALSE | FALSE | FALSE | [C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. | A.sanguinicola_A.urinae |
| 1084 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Vancomycin | Aerococcus sanguinicola and urinae | NA | 1 | 1 | FALSE | FALSE | FALSE | [A] Non-wild type isolates were not available when developing the disk diffusion method. | A.sanguinicola_A.urinae |
| 1085 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Vancomycin | Aerococcus sanguinicola and urinae | 5 mcg | 16 | 16 | FALSE | FALSE | FALSE | [A] Non-wild type isolates were not available when developing the disk diffusion method. | A.sanguinicola_A.urinae |
| 1086 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Nitrofurantoin (uncomplicated UTI only) | Aerococcus sanguinicola and urinae | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | A.sanguinicola_A.urinae |
| 1087 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Nitrofurantoin (uncomplicated UTI only) | Aerococcus sanguinicola and urinae | 100 mcg | 16 | 16 | FALSE | FALSE | FALSE | NA | A.sanguinicola_A.urinae |
| 1088 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aerococcus sanguinicola and urinae | NA | Rifampicin | Aerococcus sanguinicola and urinae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | A.sanguinicola_A.urinae |
| 1089 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aerococcus sanguinicola and urinae | NA | Rifampicin | Aerococcus sanguinicola and urinae | 5 mcg | 25 | 25 | FALSE | FALSE | FALSE | NA | A.sanguinicola_A.urinae |
| 1090 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Benzylpenicillin | Kingella kingae | NA | 0.03 | 0.03 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1091 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Benzylpenicillin | Kingella kingae | 1 unit | 25 | 25 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1092 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Ampicillin | Kingella kingae | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | [2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility. | K.kingae |
| 1093 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Ampicillin | Kingella kingae | NA | Note | Note | FALSE | FALSE | FALSE | [2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility. | K.kingae |
| 1094 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Amoxicillin | Kingella kingae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility. | K.kingae |
| 1095 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Amoxicillin | Kingella kingae | NA | Note | Note | FALSE | FALSE | FALSE | [2] Susceptibility can be inferred from benzylpenicillin susceptibility. | [A] Infer susceptibility from benzylpenicillin susceptibility. | K.kingae |
| 1096 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Amoxicillin-clavulanic acid | Kingella kingae | NA | Note | Note | FALSE | FALSE | FALSE | [3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given. | K.kingae |
| 1097 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Amoxicillin-clavulanic acid | Kingella kingae | NA | Note | Note | FALSE | FALSE | FALSE | [3/B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given. | K.kingae |
| 1098 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Cefotaxime | Kingella kingae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1099 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Cefotaxime | Kingella kingae | 5 mcg | 27 | 27 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1100 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Ceftriaxone | Kingella kingae | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1101 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Ceftriaxone | Kingella kingae | 30 mcg | 30 | 30 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1102 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Cefuroxime iv | Kingella kingae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1103 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Cefuroxime iv | Kingella kingae | 30 mcg | 29 | 29 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1104 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Meropenem | Kingella kingae | NA | 0.03 | 0.03 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1105 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Meropenem | Kingella kingae | 10 mcg | 30 | 30 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1106 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Ciprofloxacin | Kingella kingae | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1107 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Ciprofloxacin | Kingella kingae | 5 mcg | 28 | 28 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1108 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Levofloxacin | Kingella kingae | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1109 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Levofloxacin | Kingella kingae | 5 mcg | 28 | 28 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1110 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Azithromycin | Kingella kingae | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility. | K.kingae |
| 1111 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Azithromycin | Kingella kingae | NA | Note | Note | FALSE | FALSE | FALSE | [1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility. | K.kingae |
| 1112 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Clarithromycin | Kingella kingae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility. | K.kingae |
| 1113 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Clarithromycin | Kingella kingae | NA | Note | Note | FALSE | FALSE | FALSE | [1] Susceptibility can be inferred from erythromycin susceptibility. | [A] Infer susceptibility from erythromycin susceptibility. | K.kingae |
| 1114 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Erythromycin | Kingella kingae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1115 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Erythromycin | Kingella kingae | 15 mcg | 20 | 20 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1116 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Doxycycline | Kingella kingae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | K.kingae |
| 1117 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Doxycycline | Kingella kingae | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | K.kingae |
| 1118 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Tetracycline | Kingella kingae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1119 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Tetracycline | Kingella kingae | 30 mcg | 28 | 28 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1120 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Rifampicin | Kingella kingae | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1121 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Rifampicin | Kingella kingae | 5 mcg | 20 | 20 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1122 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Kingella kingae | NA | Trimethoprim-sulfamethoxazole | Kingella kingae | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1123 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Kingella kingae | NA | Trimethoprim-sulfamethoxazole | Kingella kingae | 1.25/23.75 mcg | 28 | 28 | FALSE | FALSE | FALSE | NA | K.kingae |
| 1124 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Cefepime | Aeromonas spp. | NA | 1 | 4 | FALSE | FALSE | FALSE | NA | Aeromonas |
| 1125 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Cefepime | Aeromonas spp. | 30 mcg | 27 | 24 | FALSE | FALSE | FALSE | NA | Aeromonas |
| 1126 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Ceftazidime | Aeromonas spp. | NA | 1 | 4 | FALSE | FALSE | FALSE | NA | Aeromonas |
| 1127 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Ceftazidime | Aeromonas spp. | 10 mcg | 24 | 21 | FALSE | FALSE | FALSE | NA | Aeromonas |
| 1128 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Aztreonam | Aeromonas spp. | NA | 1 | 4 | FALSE | FALSE | FALSE | NA | Aeromonas |
| 1129 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Aztreonam | Aeromonas spp. | 30 mcg | 29 | 26 | FALSE | FALSE | FALSE | NA | Aeromonas |
| 1130 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Ciprofloxacin | Aeromonas spp. | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | Aeromonas |
| 1131 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Ciprofloxacin | Aeromonas spp. | 5 mcg | 27 | 24 | FALSE | FALSE | FALSE | NA | Aeromonas |
| 1132 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Levofloxacin | Aeromonas spp. | NA | 0.5 | 1 | FALSE | FALSE | FALSE | NA | Aeromonas |
| 1133 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Levofloxacin | Aeromonas spp. | 5 mcg | 27 | 24 | FALSE | FALSE | FALSE | NA | Aeromonas |
| 1134 | EUCAST 2019 | 9.0 | human | human | MIC | NA | Aeromonas spp. | NA | Trimethoprim-sulfamethoxazole | Aeromonas spp. | NA | 2 | 4 | FALSE | FALSE | FALSE | [A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | Aeromonas |
| 1135 | EUCAST 2019 | 9.0 | human | human | DISK | NA | Aeromonas spp. | NA | Trimethoprim-sulfamethoxazole | Aeromonas spp. | 1.25/23.75 mcg | 19 | 16 | FALSE | FALSE | FALSE | [A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | Aeromonas |
| 1136 | EUCAST 2019 | 9.0 | human | human | MIC | NA | The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis. | NA | Delamanid | The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis. | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | NA | M.tuberculosis |
| 1137 | EUCAST 2019 | 9.0 | human | human | MIC | NA | The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis. | NA | Bedaquiline | The Mycobacterium tuberculosis complex includes different species and variants such as M. tuberculosis var. canetti, M. tuberculosis var. tuberculosis, M. tuberculosis var. africanum and M. tuberculosis var. bovis. Breakpoints have only been established for M. tuberculosis var. tuberculosis. | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | M.tuberculosis |
| 1138 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ampicillin | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 1139 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ampicillin | Enterobacterales | 10 mcg | 14 | 14 | FALSE | FALSE | FALSE | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 1140 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ampicillin-sulbactam | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 1141 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ampicillin-sulbactam | Enterobacterales | 10/10 mcg | 14 | 14 | FALSE | FALSE | FALSE | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 1142 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [B] Susceptibility inferred from ampicillin. | Enterobacterales |
| 1143 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin | Enterobacterales | / mcg | Note | Note | FALSE | FALSE | FALSE | [B] Susceptibility inferred from ampicillin. | Enterobacterales |
| 1144 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 1145 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid | Enterobacterales | 20/10 mcg | 19 | 19 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 1146 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid (uncomplicated UTI only) | Enterobacterales | NA | 32 | 32 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 1147 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Amoxicillin-clavulanic acid (uncomplicated UTI only) | Enterobacterales | 20/10 mcg | 16 | 16 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 1148 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Piperacillin | Enterobacterales | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1149 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Piperacillin | Enterobacterales | 30 mcg | 20 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1150 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Piperacillin-tazobactam | Enterobacterales | NA | 8 | 16 | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 1151 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Piperacillin-tazobactam | Enterobacterales | 30/6 mcg | 20 | 17 | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 1152 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ticarcillin | Enterobacterales | NA | 8 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1153 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ticarcillin | Enterobacterales | 75 mcg | 23 | 20 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1154 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ticarcillin-clavulanic acid | Enterobacterales | NA | 8 | 16 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 1155 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ticarcillin-clavulanic acid | Enterobacterales | 75/10 mcg | 23 | 20 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 1156 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Temocillin | Enterobacterales | NA | Note | Note | FALSE | FALSE | FALSE | [5/C] Breakpoints still under consideration. | Enterobacterales |
| 1157 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Temocillin | Enterobacterales | NA | Note | Note | FALSE | FALSE | FALSE | [5/C] Breakpoints still under consideration. | Enterobacterales |
| 1158 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Mecillinam oral (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone. for E. coli | Enterobacterales |
| 1159 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Mecillinam oral (uncomplicated UTI only), E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis | Enterobacterales | 10 mcg | 15 | 15 | FALSE | FALSE | FALSE | [6] Agar dilution is the reference method for mecillinam MIC determination. | [D] Ignore isolated colonies within the inhibition zone. for E. coli | Enterobacterales |
| 1160 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefadroxil (uncomplicated UTI only) | Enterobacterales | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1161 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefadroxil (uncomplicated UTI only) | Enterobacterales | 30 mcg | 12 | 12 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1162 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefalexin (uncomplicated UTI only) | Enterobacterales | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1163 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefalexin (uncomplicated UTI only) | Enterobacterales | 30 mcg | 14 | 14 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1164 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes) | Enterobacterales | NA | 0.001 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1165 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefazolin (infections originating from the urinary tract), E. coli, and Klebsiella spp. (except K. aerogenes) | Enterobacterales | IP mcg | IP | IP | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1166 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefepime | Enterobacterales | NA | 1 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1167 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefepime | Enterobacterales | 30 mcg | 27 | 24 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1168 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefixime (uncomplicated UTI only) | Enterobacterales | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1169 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefixime (uncomplicated UTI only) | Enterobacterales | 5 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1170 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefotaxime | Enterobacterales | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1171 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefotaxime | Enterobacterales | 5 mcg | 20 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1172 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefoxitin (screen only) | Enterobacterales | 30 mcg | 19 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1173 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefpodoxime (uncomplicated UTI only) | Enterobacterales | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1174 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefpodoxime (uncomplicated UTI only) | Enterobacterales | 10 mcg | 21 | 21 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1175 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftaroline | Enterobacterales | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1176 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftaroline | Enterobacterales | 5 mcg | 23 | 23 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1177 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftazidime | Enterobacterales | NA | 1 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1178 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftazidime | Enterobacterales | 10 mcg | 22 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1179 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftazidime-avibactam | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Enterobacterales |
| 1180 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftazidime-avibactam | Enterobacterales | 10/4 mcg | 13 | 13 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Enterobacterales |
| 1181 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftibuten (infections originating from the urinary tract) | Enterobacterales | NA | 1 | 1 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1182 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftibuten (infections originating from the urinary tract) | Enterobacterales | 30 mcg | 23 | 23 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1183 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftobiprole | Enterobacterales | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1184 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftobiprole | Enterobacterales | 5 mcg | 23 | 23 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1185 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftolozane-tazobactam | Enterobacterales | NA | 2 | 2 | FALSE | FALSE | FALSE | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 1186 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftolozane-tazobactam | Enterobacterales | 30/10 mcg | 22 | 22 | FALSE | FALSE | FALSE | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 1187 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ceftriaxone | Enterobacterales | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1188 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ceftriaxone | Enterobacterales | 30 mcg | 25 | 22 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1189 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | 0.001 | 8 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1190 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefuroxime iv, E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | 30 mcg | 50 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1191 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1192 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Cefuroxime oral (uncomplicated UTI only), E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | 30 mcg | 19 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1193 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ertapenem | Enterobacterales | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1194 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ertapenem | Enterobacterales | 10 mcg | 25 | 25 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1195 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Imipenem | Enterobacterales | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1196 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Imipenem | Enterobacterales | 10 mcg | 22 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1197 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Imipenem, Morganella morganii,Proteus spp. and Providencia spp. | Enterobacterales | NA | 0.001 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1198 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Imipenem, Morganella morganii,Proteus spp. and Providencia spp. | Enterobacterales | 10 mcg | 50 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1199 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Imipenem-relebactam, Enterobacterales except Morganella spp. | Enterobacterales | NA | 2 | 2 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | Enterobacterales |
| 1200 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Imipenem-relebactam, Enterobacterales except Morganella spp. | Enterobacterales | IP mcg | IP | IP | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | Enterobacterales |
| 1201 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Meropenem | Enterobacterales | NA | 2 | 8 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1202 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Meropenem | Enterobacterales | 10 mcg | 22 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1203 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Meropenem-vaborbactam | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Enterobacterales |
| 1204 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Meropenem-vaborbactam | Enterobacterales | IP mcg | IP | IP | FALSE | FALSE | FALSE | [4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Enterobacterales |
| 1205 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Aztreonam | Enterobacterales | NA | 1 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1206 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Aztreonam | Enterobacterales | 30 mcg | 26 | 21 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1207 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ciprofloxacin | Enterobacterales | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1208 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ciprofloxacin | Enterobacterales | 5 mcg | 25 | 22 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1209 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ciprofloxacin, Salmonella spp. | Enterobacterales | NA | 0.06 | 0.06 | FALSE | FALSE | FALSE | [A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | Enterobacterales |
| 1210 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ciprofloxacin, Salmonella spp. | Enterobacterales | NA | Note | Note | FALSE | FALSE | FALSE | [A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | Enterobacterales |
| 1211 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Pefloxacin (screen only)Salmonella spp. | Enterobacterales | 5 mcg | 24 | 24 | FALSE | FALSE | FALSE | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | Enterobacterales |
| 1212 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Delafloxacin, E. coli | Enterobacterales | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [D] A disk diffusion test is not yet developed. Perform an MIC test. | Enterobacterales |
| 1213 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Delafloxacin, E. coli | Enterobacterales | NA | Note | Note | FALSE | FALSE | FALSE | [D] A disk diffusion test is not yet developed. Perform an MIC test. | Enterobacterales |
| 1214 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Levofloxacin | Enterobacterales | NA | 0.5 | 1 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1215 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Levofloxacin | Enterobacterales | 5 mcg | 23 | 19 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1216 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Moxifloxacin | Enterobacterales | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1217 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Moxifloxacin | Enterobacterales | 5 mcg | 22 | 22 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1218 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Norfloxacin (uncomplicated UTI only) | Enterobacterales | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1219 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Norfloxacin (uncomplicated UTI only) | Enterobacterales | 10 mcg | 22 | 22 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1220 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Ofloxacin | Enterobacterales | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1221 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Ofloxacin | Enterobacterales | 5 mcg | 24 | 22 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1222 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Amikacin (systemic infections) | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1223 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Amikacin (systemic infections) | Enterobacterales | 30 mcg | 18 | 18 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1224 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Amikacin (infections originating from the urinary tract) | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1225 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Amikacin (infections originating from the urinary tract) | Enterobacterales | 30 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1226 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Gentamicin (systemic infections) | Enterobacterales | NA | 2 | 2 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1227 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Gentamicin (systemic infections) | Enterobacterales | 10 mcg | 17 | 17 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1228 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Gentamicin (infections originating from the urinary tract) | Enterobacterales | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1229 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Gentamicin (infections originating from the urinary tract) | Enterobacterales | 10 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1230 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Netilmicin | Enterobacterales | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1231 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Netilmicin | Enterobacterales | NA | IE | IE | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1232 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Tobramycin (systemic infections) | Enterobacterales | NA | 2 | 2 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1233 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Tobramycin (systemic infections) | Enterobacterales | 10 mcg | 17 | 17 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 1234 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Tobramycin (infections originating from the urinary tract) | Enterobacterales | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1235 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Tobramycin (infections originating from the urinary tract) | Enterobacterales | 10 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1236 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Eravacycline, E. coli | Enterobacterales | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1237 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Eravacycline, E. coli | Enterobacterales | 20 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1238 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Tigecycline,E. coli and C. koseri | Enterobacterales | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method. | Enterobacterales |
| 1239 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Tigecycline,E. coli and C. koseri | Enterobacterales | 15 mcg | 18 | 18 | FALSE | FALSE | FALSE | [3/A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method. | Enterobacterales |
| 1240 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Chloramphenicol | Enterobacterales | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1241 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Chloramphenicol | Enterobacterales | 30 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1242 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Colistin | Enterobacterales | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Enterobacterales |
| 1243 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Colistin | Enterobacterales | NA | Note | Note | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Enterobacterales |
| 1244 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Fosfomycin iv | Enterobacterales | NA | 32 | 32 | FALSE | FALSE | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 1245 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Fosfomycin iv | Enterobacterales | 200 mcg | 24 | 24 | FALSE | FALSE | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 1246 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Fosfomycin oral (uncomplicated UTI only) | Enterobacterales | NA | 32 | 32 | FALSE | FALSE | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 1247 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Fosfomycin oral (uncomplicated UTI only) | Enterobacterales | 200 mcg | 24 | 24 | FALSE | FALSE | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 1248 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Nitrofurantoin (uncomplicated UTI only), E. coli | Enterobacterales | NA | 64 | 64 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1249 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Nitrofurantoin (uncomplicated UTI only), E. coli | Enterobacterales | 100 mcg | 11 | 11 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1250 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Nitroxoline (uncomplicated UTI only), E. coli | Enterobacterales | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1251 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Nitroxoline (uncomplicated UTI only), E. coli | Enterobacterales | 30 mcg | 15 | 15 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1252 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Trimethoprim (uncomplicated UTI only) | Enterobacterales | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1253 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Trimethoprim (uncomplicated UTI only) | Enterobacterales | 5 mcg | 15 | 15 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1254 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Enterobacterales | NA | Trimethoprim-sulfamethoxazole | Enterobacterales | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1255 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Enterobacterales | NA | Trimethoprim-sulfamethoxazole | Enterobacterales | 1.25/23.75 mcg | 14 | 11 | FALSE | FALSE | FALSE | NA | Enterobacterales |
| 1256 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Piperacillin | Pseudomonas spp. | NA | 0.001 | 16 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1257 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Piperacillin | Pseudomonas spp. | 30 mcg | 50 | 18 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1258 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Piperacillin-tazobactam | Pseudomonas spp. | NA | 0.001 | 16 | FALSE | FALSE | FALSE | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 1259 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Piperacillin-tazobactam | Pseudomonas spp. | 30/6 mcg | 50 | 18 | FALSE | FALSE | FALSE | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 1260 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ticarcillin | Pseudomonas spp. | NA | 0.001 | 16 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1261 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ticarcillin | Pseudomonas spp. | 75 mcg | 50 | 18 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1262 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ticarcillin-clavulanic acid | Pseudomonas spp. | NA | 0.001 | 16 | FALSE | FALSE | FALSE | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Pseudomonas |
| 1263 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ticarcillin-clavulanic acid | Pseudomonas spp. | 75/10 mcg | 50 | 18 | FALSE | FALSE | FALSE | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Pseudomonas |
| 1264 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Cefepime | Pseudomonas spp. | NA | 0.001 | 8 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1265 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Cefepime | Pseudomonas spp. | 30 mcg | 50 | 21 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1266 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftazidime | Pseudomonas spp. | NA | 0.001 | 8 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1267 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftazidime | Pseudomonas spp. | 10 mcg | 50 | 17 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1268 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftazidime-avibactam, P. aeruginosa | Pseudomonas spp. | NA | 8 | 8 | FALSE | FALSE | FALSE | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Pseudomonas |
| 1269 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftazidime-avibactam, P. aeruginosa | Pseudomonas spp. | 10/4 mcg | 17 | 17 | FALSE | FALSE | FALSE | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Pseudomonas |
| 1270 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftobiprole | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1271 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftobiprole | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1272 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ceftolozane-tazobactam, P. aeruginosa | Pseudomonas spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 1273 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ceftolozane-tazobactam, P. aeruginosa | Pseudomonas spp. | 30/10 mcg | 24 | 24 | FALSE | FALSE | FALSE | [3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 1274 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Imipenem | Pseudomonas spp. | NA | 0.001 | 4 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1275 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Imipenem | Pseudomonas spp. | 10 mcg | 50 | 20 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1276 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Imipenem-relebactam, P. aeruginosa | Pseudomonas spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | Pseudomonas |
| 1277 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Imipenem-relebactam, P. aeruginosa | Pseudomonas spp. | IP mcg | IP | IP | FALSE | FALSE | FALSE | [1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | Pseudomonas |
| 1278 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Meropenem | Pseudomonas spp. | NA | 2 | 8 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1279 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Meropenem | Pseudomonas spp. | 10 mcg | 24 | 18 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1280 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Meropenem-vaborbactam, P. aeruginosa | Pseudomonas spp. | NA | 8 | 8 | FALSE | FALSE | FALSE | [2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Pseudomonas |
| 1281 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Meropenem-vaborbactam, P. aeruginosa | Pseudomonas spp. | IP mcg | IP | IP | FALSE | FALSE | FALSE | [2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Pseudomonas |
| 1282 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Aztreonam | Pseudomonas spp. | NA | 0.001 | 16 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1283 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Aztreonam | Pseudomonas spp. | 30 mcg | 50 | 18 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1284 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Ciprofloxacin | Pseudomonas spp. | NA | 0.001 | 0.5 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1285 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Ciprofloxacin | Pseudomonas spp. | 5 mcg | 50 | 26 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1286 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Delafloxacin | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1287 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Delafloxacin | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1288 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Levofloxacin | Pseudomonas spp. | NA | 0.001 | 1 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1289 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Levofloxacin | Pseudomonas spp. | 5 mcg | 50 | 22 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1290 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Amikacin (systemic infections) | Pseudomonas spp. | NA | 16 | 16 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Pseudomonas |
| 1291 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Amikacin (systemic infections) | Pseudomonas spp. | 30 mcg | 15 | 15 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Pseudomonas |
| 1292 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Amikacin (infections originating from the urinary tract) | Pseudomonas spp. | NA | 16 | 16 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1293 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Amikacin (infections originating from the urinary tract) | Pseudomonas spp. | 30 mcg | 15 | 15 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1294 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Gentamicin (systemic infections) | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1295 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Gentamicin (systemic infections) | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1296 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Gentamicin (infections originating from the urinary tract) | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1297 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Gentamicin (infections originating from the urinary tract) | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1298 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Netilmicin | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1299 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Netilmicin | Pseudomonas spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1300 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Tobramycin (systemic infections) | Pseudomonas spp. | NA | 2 | 2 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Pseudomonas |
| 1301 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Tobramycin (systemic infections) | Pseudomonas spp. | 10 mcg | 18 | 18 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Pseudomonas |
| 1302 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Tobramycin (infections originating from the urinary tract) | Pseudomonas spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1303 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Tobramycin (infections originating from the urinary tract) | Pseudomonas spp. | 10 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | Pseudomonas |
| 1304 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Pseudomonas spp. | NA | Colistin | Pseudomonas spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Pseudomonas |
| 1305 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Pseudomonas spp. | NA | Colistin | Pseudomonas spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Pseudomonas |
| 1306 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Stenotrophomonas maltophilia | NA | Trimethoprim-sulfamethoxazole | Stenotrophomonas maltophilia | NA | 0.001 | 4 | FALSE | FALSE | FALSE | [A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | S.maltophilia |
| 1307 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Stenotrophomonas maltophilia | NA | Trimethoprim-sulfamethoxazole | Stenotrophomonas maltophilia | 1.25/23.75 mcg | 50 | 16 | FALSE | FALSE | FALSE | [A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | S.maltophilia |
| 1308 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ampicillin-sulbactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1309 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ampicillin-sulbactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1310 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Piperacillin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1311 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Piperacillin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1312 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Piperacillin-tazobactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1313 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Piperacillin-tazobactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1314 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ticarcillin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1315 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ticarcillin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1316 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ticarcillin-clavulanic acid | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1317 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ticarcillin-clavulanic acid | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1318 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Imipenem | Acinetobacter spp. | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1319 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Imipenem | Acinetobacter spp. | 10 mcg | 24 | 21 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1320 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Imipenem-relebactam | Acinetobacter spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | Acinetobacter |
| 1321 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Imipenem-relebactam | Acinetobacter spp. | IP mcg | IP | IP | FALSE | FALSE | FALSE | [1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | Acinetobacter |
| 1322 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Meropenem | Acinetobacter spp. | NA | 2 | 8 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1323 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Meropenem | Acinetobacter spp. | 10 mcg | 21 | 15 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1324 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Meropenem-vaborbactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1325 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Meropenem-vaborbactam | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1326 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Ciprofloxacin | Acinetobacter spp. | NA | 0.001 | 1 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1327 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Ciprofloxacin | Acinetobacter spp. | 5 mcg | 50 | 21 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1328 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Delafloxacin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1329 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Delafloxacin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1330 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Levofloxacin | Acinetobacter spp. | NA | 0.5 | 1 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1331 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Levofloxacin | Acinetobacter spp. | 5 mcg | 23 | 20 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1332 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Amikacin (systemic infections) | Acinetobacter spp. | NA | 8 | 8 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1333 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Amikacin (systemic infections) | Acinetobacter spp. | 30 mcg | 19 | 19 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1334 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Amikacin (infections originating from the urinary tract) | Acinetobacter spp. | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1335 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Amikacin (infections originating from the urinary tract) | Acinetobacter spp. | 30 mcg | 19 | 19 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1336 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Gentamicin (systemic infections) | Acinetobacter spp. | NA | 4 | 4 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1337 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Gentamicin (systemic infections) | Acinetobacter spp. | 10 mcg | 17 | 17 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1338 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Gentamicin (infections originating from the urinary tract) | Acinetobacter spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1339 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Gentamicin (infections originating from the urinary tract) | Acinetobacter spp. | 10 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1340 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Netilmicin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1341 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Netilmicin | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1342 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Tobramycin (systemic infections) | Acinetobacter spp. | NA | 4 | 4 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1343 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Tobramycin (systemic infections) | Acinetobacter spp. | 10 mcg | 17 | 17 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Acinetobacter |
| 1344 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Tobramycin (infections originating from the urinary tract) | Acinetobacter spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1345 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Tobramycin (infections originating from the urinary tract) | Acinetobacter spp. | 10 mcg | 17 | 17 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1346 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Eravacycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1347 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Eravacycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1348 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Minocycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1349 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Minocycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1350 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Tigecycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1351 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Tigecycline | Acinetobacter spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1352 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Colistin | Acinetobacter spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Acinetobacter |
| 1353 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Colistin | Acinetobacter spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Use an MIC method (broth microdilution only). | Acinetobacter |
| 1354 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Acinetobacter spp. | NA | Trimethoprim-sulfamethoxazole | Acinetobacter spp. | NA | 2 | 4 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1355 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Acinetobacter spp. | NA | Trimethoprim-sulfamethoxazole | Acinetobacter spp. | 1.25/23.75 mcg | 14 | 11 | FALSE | FALSE | FALSE | NA | Acinetobacter |
| 1356 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Benzylpenicillin,S. aureus | Staphylococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase. | Staphylococcus |
| 1357 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Benzylpenicillin,S. aureus | Staphylococcus spp. | 1 unit | 26 | 26 | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase. | Staphylococcus |
| 1358 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Benzylpenicillin,S. lugdunensis | Staphylococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1359 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Benzylpenicillin,S. lugdunensis | Staphylococcus spp. | 1 unit | 26 | 26 | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1360 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Benzylpenicillin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | Staphylococcus |
| 1361 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ampicillin,S. saprophyticus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1362 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ampicillin,S. saprophyticus | Staphylococcus spp. | 2 mcg | 18 | 18 | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1363 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ampicillin-sulbactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1364 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ampicillin-sulbactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1365 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Amoxicillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1366 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Amoxicillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1367 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Amoxicillin-clavulanic acid | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1368 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Amoxicillin-clavulanic acid | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1369 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Piperacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1370 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Piperacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1371 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Piperacillin-tazobactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1372 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Piperacillin-tazobactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3/D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1373 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ticarcillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | Staphylococcus |
| 1374 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ticarcillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | Staphylococcus |
| 1375 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ticarcillin-clavulanic acid | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1376 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ticarcillin-clavulanic acid | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1377 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Phenoxymethylpenicillin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1378 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Phenoxymethylpenicillin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1379 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Phenoxymethylpenicillin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2/C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 1380 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Oxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi, see Note C on cephalosporins. | Staphylococcus |
| 1381 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Oxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi, see Note C on cephalosporins. | Staphylococcus |
| 1382 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1383 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1384 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Dicloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1385 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Dicloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1386 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Flucloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1387 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Flucloxacillin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | Staphylococcus |
| 1388 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefaclor | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1389 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefaclor | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1390 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefadroxil | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1391 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefadroxil | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1392 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefalexin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1393 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefalexin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1394 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefazolin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1395 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefazolin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1396 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefepime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1397 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefepime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1398 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefotaxime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1399 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefotaxime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1400 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm. | Staphylococcus |
| 1401 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefoxitin (screen only), S. aureus and coagulase-negative staphylococci other than S. epidermidis | Staphylococcus spp. | 30 mcg | 22 | 22 | FALSE | FALSE | FALSE | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm. | Staphylococcus |
| 1402 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefoxitin (screen only), S. epidermidis | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm. | Staphylococcus |
| 1403 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefoxitin (screen only), S. epidermidis | Staphylococcus spp. | 30 mcg | 25 | 25 | FALSE | FALSE | FALSE | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm. | Staphylococcus |
| 1404 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefoxitin (screen only), S. pseudintermedius and S. schleiferi | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [C] Cefoxitin screen for methicillin resistance in S. pseudintermediusand S. schleiferi is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm to screen for methicillin resistance. | Staphylococcus |
| 1405 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefpodoxime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1406 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefpodoxime | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1407 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ceftaroline, S. aureus (indications other than pneumonia) | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 1408 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ceftaroline, S. aureus (indications other than pneumonia) | Staphylococcus spp. | 5 mcg | 20 | 17 | FALSE | FALSE | FALSE | [5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 1409 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ceftaroline, S. aureus (pneumonia) | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | FALSE | [5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 1410 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ceftaroline, S. aureus (pneumonia) | Staphylococcus spp. | 5 mcg | 20 | 20 | FALSE | FALSE | FALSE | [5/D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 1411 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ceftobiprole, S. aureus | Staphylococcus spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [7/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing. | Staphylococcus |
| 1412 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ceftobiprole, S. aureus | Staphylococcus spp. | 5 mcg | 17 | 17 | FALSE | FALSE | FALSE | [7/F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing. | Staphylococcus |
| 1413 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ceftriaxone | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1414 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ceftriaxone | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1415 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefuroxime iv | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1416 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefuroxime iv | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1417 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Cefuroxime oral | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1418 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Cefuroxime oral | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | Staphylococcus |
| 1419 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ertapenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 1420 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ertapenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 1421 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Imipenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 1422 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Imipenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 1423 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Imipenem-relebactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 1424 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Imipenem-relebactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 1425 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Meropenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 1426 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Meropenem | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 1427 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Meropenem-vaborbactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 1428 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Meropenem-vaborbactam | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 1429 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ciprofloxacin, S. aureus | Staphylococcus spp. | NA | 0.001 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1430 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ciprofloxacin, S. aureus | Staphylococcus spp. | 5 mcg | 50 | 21 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1431 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ciprofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 0.001 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1432 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ciprofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | 5 mcg | 50 | 24 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1433 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Delafloxacin, S. aureus | Staphylococcus spp. | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [B] A disk diffusion test is not yet developed. Perform an MIC test. C.Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and "susceptible increased exposure" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Staphylococcus |
| 1434 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Delafloxacin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [B] A disk diffusion test is not yet developed. Perform an MIC test. C.Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and "susceptible increased exposure" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Staphylococcus |
| 1435 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Levofloxacin, S. aureus | Staphylococcus spp. | NA | 0.001 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1436 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Levofloxacin, S. aureus | Staphylococcus spp. | 5 mcg | 50 | 22 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1437 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Levofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 0.001 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1438 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Levofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | 5 mcg | 50 | 24 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1439 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Moxifloxacin, S. aureus | Staphylococcus spp. | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1440 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Moxifloxacin, S. aureus | Staphylococcus spp. | 5 mcg | 25 | 25 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1441 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Moxifloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1442 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Moxifloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | 5 mcg | 28 | 28 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1443 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Norfloxacin (screen only) | Staphylococcus spp. | 10 mcg | 17 | Note | FALSE | FALSE | FALSE | [C] | Staphylococcus |
| 1444 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ofloxacin, S. aureus | Staphylococcus spp. | NA | 0.001 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1445 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ofloxacin, S. aureus | Staphylococcus spp. | 5 mcg | 50 | 20 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1446 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Ofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 0.001 | 1 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1447 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Ofloxacin, Coagulase-negative staphylococci | Staphylococcus spp. | 5 mcg | 50 | 24 | FALSE | FALSE | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | Staphylococcus |
| 1448 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Amikacin, S. aureus | Staphylococcus spp. | NA | 8 | 8 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1449 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Amikacin, S. aureus | Staphylococcus spp. | 30 mcg | 18 | 18 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1450 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Amikacin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 8 | 8 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1451 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Amikacin, Coagulase-negative staphylococci | Staphylococcus spp. | 30 mcg | 22 | 22 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1452 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Gentamicin, S. aureus | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1453 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Gentamicin, S. aureus | Staphylococcus spp. | 10 mcg | 18 | 18 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1454 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Gentamicin,Coagulase-negative staphylococci | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1455 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Gentamicin,Coagulase-negative staphylococci | Staphylococcus spp. | 10 mcg | 22 | 22 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1456 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Netilmicin | Staphylococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 1457 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Netilmicin | Staphylococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 1458 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Tobramycin, S. aureus | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1459 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Tobramycin, S. aureus | Staphylococcus spp. | 10 mcg | 18 | 18 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1460 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Tobramycin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 1 | 1 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1461 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Tobramycin, Coagulase-negative staphylococci | Staphylococcus spp. | 10 mcg | 22 | 22 | FALSE | FALSE | TRUE | [1/A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy." For more information, see http://www.eucast.org/guidance_documents/. | Staphylococcus |
| 1462 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Dalbavancin | Staphylococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1463 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Dalbavancin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1464 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Oritavancin, S. aureus | Staphylococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1465 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Oritavancin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1466 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Teicoplanin, S. aureus | Staphylococcus spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1467 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Teicoplanin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1468 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Teicoplanin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1469 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Teicoplanin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1470 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Telavancin,MRSA | Staphylococcus spp. | NA | 0.125 | 0.125 | FALSE | FALSE | FALSE | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1471 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Telavancin,MRSA | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1472 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Vancomycin, S. aureus | Staphylococcus spp. | NA | 2 | 2 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1473 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Vancomycin, S. aureus | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1474 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Vancomycin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1475 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Vancomycin, Coagulase-negative staphylococci | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 1476 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Azithromycin | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 1477 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Azithromycin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 1478 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Clarithromycin | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 1479 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Clarithromycin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 1480 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Erythromycin | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 1481 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Erythromycin | Staphylococcus spp. | 15 mcg | 21 | 18 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 1482 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Roxithromycin | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 1483 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Roxithromycin | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 1484 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Telithromycin | Staphylococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 1485 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Telithromycin | Staphylococcus spp. | NA | IE | IE | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 1486 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Clindamycin | Staphylococcus spp. | NA | 0.25 | 0.5 | FALSE | FALSE | FALSE | [B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | Staphylococcus |
| 1487 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Clindamycin | Staphylococcus spp. | 2 mcg | 22 | 19 | FALSE | FALSE | FALSE | [B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | Staphylococcus |
| 1488 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Quinupristin-dalfopristin | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 1489 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Quinupristin-dalfopristin | Staphylococcus spp. | 15 mcg | 21 | 18 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 1490 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Doxycycline | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 1491 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Doxycycline | Staphylococcus spp. | NA | Note | Note | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 1492 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Eravacycline, S. aureus | Staphylococcus spp. | NA | 0.25 | 0.25 | FALSE | FALSE | FALSE | [B] The zone diameter breakpoint is valid for MSSA only. For MRSA, perform an MIC test. | Staphylococcus |
| 1493 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Eravacycline, S. aureus | Staphylococcus spp. | 20 mcg | 20 | 20 | FALSE | FALSE | FALSE | [B] The zone diameter breakpoint is valid for MSSA only. For MRSA, perform an MIC test. | Staphylococcus |
| 1494 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Minocycline | Staphylococcus spp. | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 1495 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Minocycline | Staphylococcus spp. | 30 mcg | 23 | 23 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 1496 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Tetracycline | Staphylococcus spp. | NA | 1 | 2 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 1497 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Tetracycline | Staphylococcus spp. | 30 mcg | 22 | 19 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 1498 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Tigecycline | Staphylococcus spp. | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | Staphylococcus |
| 1499 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Tigecycline | Staphylococcus spp. | 15 mcg | 19 | 19 | FALSE | FALSE | FALSE | [3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | Staphylococcus |
| 1500 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Linezolid | Staphylococcus spp. | NA | 4 | 4 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 1501 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Linezolid | Staphylococcus spp. | 10 mcg | 21 | 21 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 1502 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Tedizolid | Staphylococcus spp. | NA | 0.5 | 0.5 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | Staphylococcus |
| 1503 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Tedizolid | Staphylococcus spp. | 2 mcg | 21 | 21 | FALSE | FALSE | FALSE | [1/A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | Staphylococcus |
| 1504 | EUCAST 2020 | 10.0 | human | human | MIC | NA | Staphylococcus spp. | NA | Chloramphenicol | Staphylococcus spp. | NA | 8 | 8 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| 1505 | EUCAST 2020 | 10.0 | human | human | DISK | NA | Staphylococcus spp. | NA | Chloramphenicol | Staphylococcus spp. | 30 mcg | 18 | 18 | FALSE | FALSE | FALSE | NA | Staphylococcus |
| The file is too large to be shown. View Raw |